CA2580141C - Cysteine engineered antibodies and conjugates - Google Patents

Cysteine engineered antibodies and conjugates Download PDF

Info

Publication number
CA2580141C
CA2580141C CA2580141A CA2580141A CA2580141C CA 2580141 C CA2580141 C CA 2580141C CA 2580141 A CA2580141 A CA 2580141A CA 2580141 A CA2580141 A CA 2580141A CA 2580141 C CA2580141 C CA 2580141C
Authority
CA
Canada
Prior art keywords
antibody
seq
cysteine
frac acc
cysteine engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2580141A
Other languages
English (en)
French (fr)
Other versions
CA2580141A1 (en
Inventor
Charles W. Eigenbrot
Jagath Reddy Junutula
Henry Lowman
Helga E. Raab
Richard Vandlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2580141A1 publication Critical patent/CA2580141A1/en
Application granted granted Critical
Publication of CA2580141C publication Critical patent/CA2580141C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2580141A 2004-09-23 2005-09-22 Cysteine engineered antibodies and conjugates Expired - Lifetime CA2580141C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61246804P 2004-09-23 2004-09-23
US60/612,468 2004-09-23
US69635305P 2005-06-30 2005-06-30
US60/696,353 2005-06-30
PCT/US2005/034353 WO2006034488A2 (en) 2004-09-23 2005-09-22 Cysteine engineered antibodies and conjugates

Publications (2)

Publication Number Publication Date
CA2580141A1 CA2580141A1 (en) 2006-03-30
CA2580141C true CA2580141C (en) 2013-12-10

Family

ID=36090710

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2580141A Expired - Lifetime CA2580141C (en) 2004-09-23 2005-09-22 Cysteine engineered antibodies and conjugates

Country Status (18)

Country Link
US (6) US7521541B2 (enExample)
EP (2) EP3088004B1 (enExample)
JP (2) JP4948413B2 (enExample)
KR (1) KR101270829B1 (enExample)
CN (2) CN101065151B (enExample)
AU (1) AU2005286607B2 (enExample)
BR (1) BRPI0516284A (enExample)
CA (1) CA2580141C (enExample)
DK (1) DK1791565T3 (enExample)
ES (2) ES2579805T3 (enExample)
HU (1) HUE030079T2 (enExample)
IL (1) IL181584A (enExample)
NZ (2) NZ553500A (enExample)
PL (1) PL1791565T3 (enExample)
RU (1) RU2412947C2 (enExample)
SI (1) SI1791565T1 (enExample)
TR (1) TR201808537T4 (enExample)
WO (1) WO2006034488A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11938194B2 (en) 2017-02-28 2024-03-26 Seagen Inc. Cysteine mutated antibodies for conjugation

Families Citing this family (1280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
DK1086223T3 (da) 1998-06-01 2009-11-30 Agensys Inc Nye serpentintransmembranantigener udtrykt i humane cancerformer og anvendelser deraf
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP2163256B1 (en) 2001-05-11 2015-09-02 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
CA2459318C (en) 2001-09-06 2017-09-26 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US20070207142A1 (en) * 2002-05-08 2007-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
SI2357006T1 (sl) 2002-07-31 2016-01-29 Seattle Genetics, Inc. Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
US20110042260A1 (en) * 2003-04-10 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
AU2005216251B2 (en) * 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
AU2005218642B2 (en) 2004-03-02 2011-04-28 Seagen Inc. Partially loaded antibodies and methods of their conjugation
DK1742966T3 (da) 2004-04-22 2014-02-03 Agensys Inc Antistoffer og molekyler afledt deraf som binder til STEAP-1 proteiner
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1817336B1 (en) 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
EP2325206B1 (en) 2004-11-12 2014-03-19 Xencor, Inc. Fc variants with altered binding to fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006104989A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
USRE47223E1 (en) * 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ES2585357T3 (es) 2005-07-07 2016-10-05 Seattle Genetics, Inc. Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
WO2008020827A2 (en) * 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
ES2363891T3 (es) 2006-03-20 2011-08-18 The Regents Of The University Of California Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer.
HRP20140172T1 (hr) * 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
GB0619291D0 (en) * 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
AU2013202022B2 (en) * 2006-10-27 2015-06-11 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
CN101573384B (zh) * 2006-10-27 2013-02-20 健泰科生物技术公司 抗体和免疫偶联物及其用途
CA2667019C (en) * 2006-10-27 2016-03-29 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
CA2699837C (en) 2006-12-01 2017-06-13 Seattle Genetics, Inc. Variant target binding agents and uses thereof
MX338185B (es) 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
PE20081760A1 (es) 2007-02-09 2009-01-01 Genentech Inc Anticuerpos anti-robo4 y sus usos
EP2134854B1 (en) 2007-03-15 2015-04-15 Ludwig Institute for Cancer Research Ltd. Treatment method using egfr antibodies and src inhibitors and related formulations
JP5394246B2 (ja) * 2007-03-30 2014-01-22 ジェネンテック， インコーポレイテッド 抗体及びイムノコンジュゲートとこれらの使用方法
JP5290276B2 (ja) * 2007-05-08 2013-09-18 ジェネンテック， インコーポレイテッド システイン改変抗ｍｕｃ１６抗体および抗体−薬物結合体
PL4365189T3 (pl) 2007-07-09 2025-05-26 F. Hoffmann-La Roche Ag Zapobieganie redukcji wiązania disiarczkowego podczas rekombinacyjnego wytwarzania polipeptydów
US8247423B2 (en) 2007-07-12 2012-08-21 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
EP2641618A3 (en) 2007-07-16 2013-10-23 Genentech, Inc. Humanized anti-CD79B antibodies and immunoconjugates and methods of use
CL2008002085A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
CN101835801B (zh) * 2007-08-08 2014-09-10 诺维信生物制药丹麦公司 转铁蛋白变体和偶联物
WO2009023265A1 (en) 2007-08-14 2009-02-19 Ludwig Institute For Cancer Research Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
WO2009097017A2 (en) * 2007-09-18 2009-08-06 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
US7959861B2 (en) * 2007-09-19 2011-06-14 Stc.Unm Integrated affinity microcolumns and affinity capillary electrophoresis
WO2009042618A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
KR102339457B1 (ko) 2007-09-26 2021-12-14 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
CA2700410C (en) * 2007-10-03 2020-10-06 Cornell University Treatment of proliferative disorders using antibodies to psma
CN101835803B (zh) * 2007-10-19 2016-05-25 健泰科生物技术公司 半胱氨酸改造的抗tenb2抗体和抗体药物偶联物
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
CN102083460A (zh) * 2008-01-18 2011-06-01 米迪缪尼有限公司 用于位点特异性偶联的半胱氨酸工程化抗体
CN104650230A (zh) * 2008-01-31 2015-05-27 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
US8742076B2 (en) * 2008-02-01 2014-06-03 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
CA2718942A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
MY166445A (en) 2008-03-18 2018-06-27 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents,and methods of use
MX2010011808A (es) * 2008-04-30 2011-03-04 Immunogen Inc Conjugados potentes y enlazadores hidrofilicos.
CN104524590B (zh) * 2008-04-30 2019-06-21 伊缪诺金公司 交联剂和它们的用途
AU2015202204A1 (en) * 2008-04-30 2015-05-14 Immunogen, Inc. Cross-linkers and their uses
MX2010014079A (es) 2008-06-20 2011-02-22 Novartis Ag Inmunoglobulinas con agregacion reducida.
PT2310970E (pt) 2008-06-20 2013-07-26 Massachusetts Inst Technology Métodos de identificação de regiões de ligação macromolecular e de regiões predispostas à agregação nas proteínas e suas utilizações
JP5438922B2 (ja) * 2008-06-25 2014-03-12 日東電工株式会社 核酸の製造方法
DE102008033871A1 (de) * 2008-06-26 2009-12-31 InBio Prof.Jürgen Büddefeld Dr.Peter Klauth Prof.Manfred Rietz GbR (vertretungsberechtigter Gesellschafter: Dr.Peter Klauth, 41189 Mönchengladbach) Abstandsgesteuerte Energietransfer-Farbstoffkomplexe
CN105153300A (zh) 2008-06-30 2015-12-16 艾斯巴技术-诺华有限责任公司 官能化的多肽
BRPI0915460A2 (pt) 2008-07-10 2015-11-10 Esbatech Alcon Biomed Res Unit métodos e composições para a liberação intensificada de macromoléculas
AR072804A1 (es) 2008-07-15 2010-09-22 Genentech Inc Conjugados derivados de antraciclina,proceso para su preparacion,composiciones farmaceuticas que los contienen y su uso como agentes antitumorales.
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
EP2358393A1 (en) * 2008-11-20 2011-08-24 F.Hoffmann-La Roche Ag Therapeutic protein formulations
CA2749115C (en) * 2009-01-09 2022-06-21 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
SG172789A1 (en) * 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP2398504B1 (en) * 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
SG173812A1 (en) 2009-02-27 2011-09-29 Genentech Inc Methods and compositions for protein labelling
CA2753702C (en) 2009-03-05 2017-01-03 Medarex, Inc. Fully human antibodies specific to cadm1
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
MA33210B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Nouveaux anticorps anti-a5b1 et leurs utilisations
US8603792B2 (en) 2009-03-27 2013-12-10 Life Technologies Corporation Conjugates of biomolecules to nanoparticles
EP2414399A1 (en) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Anti-fcrh5 antibodies and immunoconjugates and methods of use
CA2756988A1 (en) 2009-04-01 2010-10-07 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates
CN102369215B (zh) 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
DK2417156T3 (en) 2009-04-07 2015-03-02 Roche Glycart Ag Trivalent, bispecific antibodies
RS58810B1 (sr) 2009-06-03 2019-07-31 Immunogen Inc Metodi konjugacije
BRPI1013016A2 (pt) * 2009-06-04 2016-03-29 Massachusetts Inst Technology "métodos para identificação de locais para conjugação de igg"
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN102802661B (zh) 2009-06-22 2016-01-13 米迪缪尼有限公司 用于位点特异性偶联的工程改造的Fc区
KR101962476B1 (ko) 2009-07-03 2019-03-26 아비펩 피티와이 리미티트 면역성 접합체 및 그 제조방법
CN102666583B (zh) 2009-07-15 2015-11-25 Aimm医疗股份公司 革兰氏阳性细菌特异性结合化合物
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2475682B1 (en) 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
JP6091894B2 (ja) 2009-09-16 2017-03-15 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
EP2486023A4 (en) * 2009-10-06 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
US8734798B2 (en) * 2009-10-27 2014-05-27 Ucb Pharma S.A. Function modifying NAv 1.7 antibodies
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
RU2607374C2 (ru) 2009-10-30 2017-01-10 Новозаймс Байофарма Дк А/С Варианты альбумина
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
WO2011069019A2 (en) 2009-12-02 2011-06-09 David Ho J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
US20110165155A1 (en) * 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
CN102770456B (zh) * 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
EP2513148B1 (en) * 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
US9315581B2 (en) * 2009-12-23 2016-04-19 A Vipep Pty Limited Immuno-conjugates and methods for producing them
US20110159588A1 (en) 2009-12-30 2011-06-30 Kui Lin Methods for Modulating a PDGF-AA Mediated Biological Response
UA115517C2 (uk) 2010-02-08 2017-11-27 Ейдженсіс, Інк. Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b
JP5981853B2 (ja) 2010-02-18 2016-08-31 ジェネンテック， インコーポレイテッド ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
KR20130004579A (ko) 2010-02-23 2013-01-11 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
KR101899835B1 (ko) 2010-03-24 2018-09-19 제넨테크, 인크. 항-ｌｒｐ６ 항체
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US9169328B2 (en) 2010-03-26 2015-10-27 Memorial Sloan Kettering Cancer Center Antibodies to MUC16 and methods of use thereof
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
EP2554669B1 (en) * 2010-03-26 2018-09-19 Kyowa Hakko Kirin Co., Ltd. Novel antibody having modification site introduced therein, and antibody fragment
US8927695B2 (en) 2010-03-30 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University Protein-based assays for screening of the IgE-receptor interaction
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
MX368648B (es) 2010-04-15 2019-10-09 Seattle Genetics Inc Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas.
NZ602932A (en) 2010-04-15 2014-08-29 Seattle Genetics Inc Targeted pyrrolobenzodiazapine conjugates
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
HUE030846T2 (en) 2010-04-21 2017-06-28 Syntarga Bv Conjugates of cc-1065 analogs and bifunctional linkers
EP2564203B1 (en) * 2010-04-27 2017-06-07 Ventana Medical Systems, Inc. Antibody-nanoparticle conjugates and methods for making and using such conjugates
BR112012028326A2 (pt) 2010-05-06 2017-03-21 Novartis Ag anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
ES2949159T3 (es) 2010-05-06 2023-09-26 Novartis Ag Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CA2799915C (en) 2010-05-25 2023-09-26 Genentech, Inc. Methods of purifying polypeptides
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
CA2801064A1 (en) * 2010-06-01 2011-12-08 Advanced Proteome Therapeutics Inc. Crosslinking of proteins and other entities via conjugates of alpha-haloacetophenones, benzyl halides, quinones, and their derivatives
CN103119442A (zh) 2010-06-03 2013-05-22 霍夫曼-拉罗奇有限公司 抗体和免疫偶联物的免疫peg成像及其用途
WO2011156328A1 (en) * 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
KR101885388B1 (ko) 2010-06-18 2018-08-03 제넨테크, 인크. 항-Ａｘｌ 항체 및 사용 방법
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
CA2803792A1 (en) 2010-07-09 2012-01-12 Genentech, Inc. Anti-neuropilin antibodies and methods of use
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
EP3029066B1 (en) 2010-07-29 2019-02-20 Xencor, Inc. Antibodies with modified isoelectric points
RU2013106216A (ru) 2010-08-03 2014-09-10 Ф. Хоффманн-Ля Рош Аг Биомаркеры хронической лимфоцитарной лейкемии
RU2584597C2 (ru) 2010-08-13 2016-05-20 Рош Гликарт Аг Антитела против а2 тенасцина с и способы их применения
ES2655616T3 (es) 2010-08-13 2018-02-20 Roche Glycart Ag Anticuerpos anti-FAP y procedimientos de uso
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
CA2805054A1 (en) 2010-08-25 2012-03-01 F. Hoffmann-La Roche Ag Antibodies against il-18r1 and uses thereof
AU2011295919A1 (en) 2010-08-31 2013-03-07 Genentech, Inc. Biomarkers and methods of treatment
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IL319612A (en) 2010-09-29 2025-05-01 Seagen Inc Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
JP6006640B2 (ja) 2010-10-29 2016-10-12 株式会社ペルセウスプロテオミクス 高い内在化能力を有する抗ｃｄｈ３抗体
CN103269712B (zh) 2010-11-03 2016-09-21 伊缪诺金公司 包含新型安丝菌素衍生物的细胞毒性剂
AU2011325871B2 (en) 2010-11-05 2016-02-04 Medvet Science Pty Ltd Markers of endothelial progenitor cells and uses thereof
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
JP6014596B2 (ja) * 2010-11-09 2016-10-25 メディミューン，エルエルシー 均一コンジュゲーションのための抗体足場
US8772457B2 (en) 2010-11-10 2014-07-08 Genentech, Inc. BACE1 antibodies
CN103313990B (zh) 2010-11-17 2016-07-20 基因泰克公司 丙氨酰美登醇抗体偶联物
CA2820630A1 (en) * 2010-12-09 2012-06-14 Bayer Healthcare Llc Dimeric molecular complexes with free cysteine residues and conjugates thereof
WO2012083132A2 (en) 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
NZ610976A (en) 2010-12-20 2015-07-31 Genentech Inc Anti-mesothelin antibodies and immunoconjugates
SG191219A1 (en) 2010-12-22 2013-07-31 Genentech Inc Anti-pcsk9 antibodies and methods of use
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CN103415621A (zh) 2011-01-14 2013-11-27 雷德伍德生物科技股份有限公司 醛标记免疫球蛋白多肽及其使用方法
WO2012106671A1 (en) * 2011-02-03 2012-08-09 Integrated Diagnostics, Inc. Psa capture agents, compositions, methods and preparation thereof
EP2673003B1 (en) 2011-02-10 2018-11-07 Ruprecht-Karls-Universität Heidelberg Hydrophobic modified peptides for liver specific diagnosis
EP2675479B1 (en) 2011-02-15 2016-01-13 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
MX342240B (es) 2011-04-07 2016-09-21 Genentech Inc Anticuerpos anti-fgfr4 y metodos de uso.
US9598496B2 (en) 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
LT2710035T (lt) 2011-05-16 2017-06-26 F. Hoffmann-La Roche Ag Fgfr1 agonistai ir jų naudojimo būdai
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
EA029797B1 (ru) 2011-06-21 2018-05-31 Иммуноджен, Инк. Новые производные майтанзиноида с пептидным линкером и их конъюгаты
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
CN103781801B (zh) 2011-08-23 2018-02-09 罗切格利卡特公司 包含两个Fab片段的无Fc的抗体及使用方法
MX356947B (es) 2011-08-23 2018-06-20 Roche Glycart Ag Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso.
CN103890006A (zh) 2011-08-23 2014-06-25 罗切格利卡特公司 抗mcsp抗体
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
MX2014003094A (es) 2011-09-15 2014-04-25 Genentech Inc Metodos para promover diferenciacion.
WO2013040188A1 (en) * 2011-09-15 2013-03-21 Cytodyn, Inc. Anti-cd11a antibodies and uses thereof
KR20140064971A (ko) 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
MX341524B (es) 2011-09-20 2016-08-24 Medimmune Ltd Pirrolobenzodiazepinas como compuestos pbd dimericos asimetricos para inclusion en conjugados dirigidos.
US9663573B2 (en) 2011-10-05 2017-05-30 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CA3182462A1 (en) 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
EP2751110B1 (en) 2011-10-14 2017-04-19 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
AU2012322613B2 (en) 2011-10-14 2016-04-21 Medimmune Limited Pyrrolobenzodiazepines and targeted conjugates
LT2766393T (lt) 2011-10-14 2018-10-10 F. Hoffmann-La Roche Ag Antikūnai prieš htra1 ir jų naudojimo būdai
SG11201401406YA (en) * 2011-10-14 2014-05-29 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
KR101891859B1 (ko) 2011-10-14 2018-08-24 메디뮨 리미티드 피롤로벤조디아제핀
EP2766000A2 (en) 2011-10-15 2014-08-20 F.Hoffmann-La Roche Ag Scd1 antagonists for treating cancer
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
EP2776051A4 (en) 2011-10-28 2015-06-17 Hoffmann La Roche THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
PL3257564T5 (pl) 2011-11-02 2024-10-07 F. Hoffmann-La Roche Ag Chromatografia elucyjna z przeładowaniem
AU2012336069A1 (en) 2011-11-07 2014-05-22 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
BR112014012005A2 (pt) 2011-11-21 2017-12-19 Genentech Inc composições, métodos, formulação farmacêutica e artigo
BR112014012590A8 (pt) 2011-11-23 2017-12-19 Igenica Inc Anticorpos anti-cd98 e métodos de uso dos mesmos
WO2013085925A1 (en) * 2011-12-05 2013-06-13 Igenica, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
CA2859755C (en) * 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
CA2862424A1 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
IN2014DN05885A (enExample) 2012-01-18 2015-06-05 Hoffmann La Roche
US20150011736A1 (en) 2012-01-20 2015-01-08 Sea Lane Biotechnologies, Llc Binding molecule conjugates
JP6486686B2 (ja) 2012-02-10 2019-03-20 ジェネンテック， インコーポレイテッド 単鎖抗体及び他のヘテロ多量体
WO2013120056A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
TW201336851A (zh) 2012-02-13 2013-09-16 必治妥美雅史谷比公司 烯二炔化合物，其共軛物及彼等之用途與方法
BR112014018005B1 (pt) 2012-02-15 2021-06-29 F. Hoffmann-La Roche Ag Uso de um complexo não covalente imobilizado
PE20150091A1 (es) 2012-02-24 2015-02-16 Stem Centrx Inc Anticuerpos anti-sez6 y metodos de empleo
CN104220458B (zh) * 2012-02-24 2018-08-14 阿特根公司 结合有含半胱氨酸残基的基序的修饰抗体，含该修饰抗体的修饰抗体-药物缀合物以及其制造方法
ES2812849T3 (es) 2012-02-24 2021-03-18 Abbvie Stemcentrx Llc Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
MX2014011500A (es) 2012-03-27 2014-12-05 Genentech Inc Diagnosticos y tratamientos relacionados a inhibidores her3.
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
CN104220595A (zh) 2012-04-04 2014-12-17 株式会社英仙蛋白质科学 抗cdh3(p-钙粘着蛋白）抗体的药剂偶联物
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
US9056910B2 (en) 2012-05-01 2015-06-16 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
CN104662000B (zh) 2012-05-15 2018-08-17 索伦托医疗有限公司 药物偶联物及其偶联方法和用途
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
AU2013266604B2 (en) 2012-05-21 2016-09-08 Genentech, Inc. Anti-Ly6E antibodies and immunoconjugates and methods of use
WO2013177470A1 (en) 2012-05-23 2013-11-28 Genentech, Inc. Selection method for therapeutic agents
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
EP2861624A1 (en) 2012-06-15 2015-04-22 F. Hoffmann-La Roche AG Anti-pcsk9 antibodies, formulations, dosing, and methods of use
MX2014014804A (es) 2012-06-27 2015-02-12 Hoffmann La Roche Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
CN104395339A (zh) 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
AU2013285422B2 (en) 2012-07-04 2017-04-27 F. Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
CN104394886B (zh) 2012-07-04 2017-05-24 弗·哈夫曼-拉罗切有限公司 抗茶碱抗体及使用方法
KR20150030755A (ko) 2012-07-04 2015-03-20 에프. 호프만-라 로슈 아게 항-바이오틴 항체 및 사용 방법
ES2743401T3 (es) 2012-07-05 2020-02-19 Hoffmann La Roche Sistema de expresión y secreción
KR20150030698A (ko) 2012-07-09 2015-03-20 제넨테크, 인크. 항-cd79b 항체를 포함하는 면역접합체
AU2013288930A1 (en) 2012-07-09 2014-12-04 Genentech, Inc. Immunoconjugates comprising anti-CD79b antibodies
SG11201500087VA (en) 2012-07-09 2015-02-27 Genentech Inc Immunoconjugates comprising anti-cd22 antibodies
AR091701A1 (es) 2012-07-09 2015-02-25 Genentech Inc Anticuerpos anti-cd22 e inmunoconjugados
MX361337B (es) 2012-07-13 2018-12-04 Roche Glycart Ag Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares.
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
KR20150032886A (ko) 2012-08-02 2015-03-30 제넨테크, 인크. 항-etbr 항체 및 면역접합체
KR20150039818A (ko) 2012-08-02 2015-04-13 제넨테크, 인크. 항-etbr 항체 및 면역접합체
WO2014022817A2 (en) 2012-08-03 2014-02-06 Novartis Ag Methods to identify amino acid residues involved in macromolecular binding and uses therefor
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
KR102355959B1 (ko) 2012-08-23 2022-01-27 어젠시스 인코포레이티드 158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US20150218220A1 (en) * 2012-09-12 2015-08-06 Brian Alan MENDELSOHN Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
DK2900676T3 (en) 2012-09-26 2019-04-08 Immunogen Inc IMPROVED PROCEDURES FOR ACYLATION OF MAYTANSINOL
WO2014052713A2 (en) 2012-09-27 2014-04-03 Massachusetts Institute Of Technology Her2-and vegf-a-binding proteins with enhanced stability
US10087250B2 (en) 2012-10-08 2018-10-02 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
US20150231240A1 (en) 2012-10-09 2015-08-20 Igenica Biotherapeutics, Inc. Anti-c16orf54 antibodies and methods of use thereof
PT2906298T (pt) 2012-10-12 2018-12-28 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpos
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
SI2906253T1 (sl) 2012-10-12 2018-11-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo proti PSMA
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
ES2713164T3 (es) 2012-10-12 2019-05-20 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
WO2014057122A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
SMT201800346T1 (it) 2012-10-12 2018-09-13 Medimmune Ltd Coniugati pirrolobenzodiazepina-anticorpo
EP2906249B1 (en) 2012-10-12 2018-06-27 MedImmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
WO2014057074A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
AU2013337264B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
CN105452290A (zh) 2012-11-08 2016-03-30 诺维信生物制药丹麦公司 白蛋白变体
CA2893794C (en) 2012-11-08 2021-11-09 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
MX2015005757A (es) 2012-11-08 2015-11-18 Hoffmann La Roche Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
MA38176A1 (fr) 2012-11-13 2017-06-30 Genentech Inc Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a
BR112015011011A2 (pt) 2012-11-15 2019-12-17 Genentech Inc cromatografia por troca de íon com gradiente de ph mediada por força iônica
JP6475631B2 (ja) * 2012-11-19 2019-02-27 バリオファルム・アクチェンゲゼルシャフト Ｃｄ２０およびｃｄ９５に結合する組換え二重特異性抗体
US9474803B2 (en) 2012-11-27 2016-10-25 Alteogen Inc. Composition for stabilizing fusion protein in which protein and FC domain are fused
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
BR112015013444B1 (pt) 2012-12-13 2022-11-01 Immunomedics, Inc Uso de um imunoconjugado
CN104994885B (zh) * 2012-12-19 2017-09-29 基因泰克公司 用于放射性卤素蛋白质标记的方法和组合物
TWI716339B (zh) 2012-12-21 2021-01-21 荷蘭商台醫（有限合夥）公司 親水性自消耗連接子及彼等之共軛物
CN110627797A (zh) 2012-12-21 2019-12-31 麦迪穆有限责任公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
JP6307519B2 (ja) 2012-12-21 2018-04-04 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピンおよびその結合体
JP6262768B2 (ja) * 2013-01-03 2018-01-17 セルトリオン， インク． 抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP3939614A1 (en) 2013-01-18 2022-01-19 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
CN103933575B (zh) 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
SI2953976T1 (sl) * 2013-02-08 2021-08-31 Novartis Ag Specifična mesta z modificiranje protiteles za izdelavo imunokonjugatov
HUE033626T2 (en) 2013-02-14 2017-12-28 Bristol Myers Squibb Co Tubulysin compounds, methods of preparation and use
RU2015139147A (ru) 2013-02-15 2017-03-21 Персеус Протеомикс Инк. Гуманизированное антитело к cdh3, его конъюгат с лекарственным средством и их применение
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
HK1211235A1 (en) 2013-02-22 2016-05-20 霍夫曼-拉罗奇有限公司 Methods of treating cancer and preventing drug resistance
US20140242083A1 (en) 2013-02-26 2014-08-28 Roche Glycart Ag Anti-mcsp antibodies
JP6423804B2 (ja) * 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤を含む複合体
JP6494533B2 (ja) 2013-02-28 2019-04-03 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
RU2708314C2 (ru) 2013-03-11 2019-12-05 Джензим Корпорейшн Гипергликозилированные связывающие полипептиды
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
EP2968596B1 (en) 2013-03-13 2019-03-06 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
WO2014159835A1 (en) 2013-03-14 2014-10-02 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
EP2968540A2 (en) 2013-03-14 2016-01-20 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
RU2015139054A (ru) 2013-03-14 2017-04-19 Дженентек, Инк. Способы лечения рака и профилактики лекарственной резистентности рака
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
AR095517A1 (es) 2013-03-15 2015-10-21 Genentech Inc ANTICUERPOS CONTRA EL RECEPTOR QUIMIOATRAYENTE EXPRESADO EN CÉLULAS T HELPER 2 (ANTI-CRTh2) Y MÉTODOS DE USO
US20140286969A1 (en) * 2013-03-15 2014-09-25 Abbvie Inc. Anti-egfr antibody drug conjugate formulations
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
MX2015012551A (es) * 2013-03-15 2016-10-26 Abbvie Biotechnology Ltd Anticuerpos anti-cd25 y sus usos.
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
RU2661111C2 (ru) 2013-03-15 2018-07-11 Ац Иммуне С.А. Антитела к тау и способы применения
HK1211963A1 (en) 2013-03-15 2016-06-03 豪夫迈．罗氏有限公司 Compositions and methods for diagnosis and treatment of hepatic cancers
JP6594855B2 (ja) 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
CA2903587C (en) 2013-03-15 2021-09-28 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
KR20220053691A (ko) 2013-03-15 2022-04-29 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
EP2968537A1 (en) 2013-03-15 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
EP3421495A3 (en) 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US20140377253A1 (en) * 2013-03-15 2014-12-25 Abbvie Biotherapeutics Inc. Fc variants
AU2014233436B2 (en) 2013-03-15 2019-12-05 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
US20160068613A1 (en) 2013-04-29 2016-03-10 Hoffmann-La Roche Inc. Fc-receptor binding modified asymmetric antibodies and methods of use
TW201920285A (zh) 2013-04-29 2019-06-01 瑞士商赫孚孟拉羅股份公司 遏止FcRn結合之抗IGF-1R抗體及其治療血管性眼疾之用途
KR20210094669A (ko) 2013-04-29 2021-07-29 에프. 호프만-라 로슈 아게 인간 fcrn-결합 변형된 항체 및 사용 방법
PH12021550015A1 (en) 2013-05-20 2022-05-11 Genentech Inc Anti-transferrin receptor antibodies and methods of use
KR20160015286A (ko) 2013-05-31 2016-02-12 제넨테크, 인크. 항-세포벽 테이코산 항체 및 접합체
BR112015029838A2 (pt) 2013-05-31 2017-09-26 Genentech Inc anticorpos, composições, ácido nucleico isolado, vetor, célula hospedeira isolada, método de produção de anticorpos, composto, conjugado de anticorpo e antibiótico, processo de elaboração do composto, intermediário entre ligante e antibiótico, método de tratamento de infecções bacterianas e método de matar staphylococcus aureus
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014197866A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
KR20160023725A (ko) * 2013-07-03 2016-03-03 서울대학교산학협력단 시스테인으로 변형된 닭의 항체 및 이를 이용한 부위-특이적 접합
RU2016104542A (ru) 2013-07-12 2017-08-17 Дженентек, Инк. Осуществление оптимизации входных условий ионообменной хроматографии
CA3012994C (en) 2013-07-31 2020-10-20 Rinat Neuroscience Corp. Engineered polypeptide conjugates
CN105722534B (zh) 2013-08-01 2019-05-31 艾更斯司股份有限公司 结合cd37蛋白的抗体药物偶联物(adc)
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
EP3906945A3 (en) 2013-08-26 2022-03-16 BioNTech Research and Development, Inc. Nucleic acids encoding human antibodies to sialyl-lewis a
EP3038634A4 (en) 2013-08-28 2017-10-11 AbbVie Stemcentrx LLC Novel sez6 modulators and methods of use
CN105873612A (zh) * 2013-08-28 2016-08-17 施特姆森特克斯股份有限公司 改造的抗-dll3缀合物以及应用方法
AU2014312215B2 (en) * 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
WO2015035180A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Method for chromatography reuse
DK3041513T3 (da) 2013-09-08 2020-10-26 Kodiak Sciences Inc Zwitterioniske faktor viii-polymerkonjugater
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
AR097685A1 (es) 2013-09-17 2016-04-06 Genentech Inc Métodos de uso de anticuerpos anti-lgr5
WO2015044083A1 (en) 2013-09-27 2015-04-02 F. Hoffmann-La Roche Ag Thermus thermophilus slyd fkbp domain specific antibodies
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
CN105745224B (zh) 2013-10-11 2019-11-05 牛津生物疗法有限公司 用于治疗癌症的针对ly75的偶联抗体
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
JP6422956B2 (ja) 2013-10-11 2018-11-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性ドメイン交換共通可変軽鎖抗体
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
RU2016117978A (ru) 2013-10-11 2017-11-17 Дженентек, Инк. Ингибиторы nsp4 и способы их применения
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
BR112016008477A2 (pt) 2013-10-18 2017-10-03 Genentech Inc Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
CN105658237B (zh) 2013-10-21 2021-03-09 基因泰克公司 抗Ly6E抗体及使用方法
CA2924873A1 (en) 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
RU2016122041A (ru) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
EP2873680A1 (en) * 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Oligopeptide and methods for producing conjugates thereof
PT3071597T (pt) 2013-11-21 2020-10-08 Hoffmann La Roche Anticorpos anti-alfa-sinucleína e métodos de utilização
WO2015089449A2 (en) 2013-12-12 2015-06-18 Stem Centrx, Inc. Novel anti-dpep3 antibodies and methods of use
AU2014362238A1 (en) 2013-12-13 2016-06-09 Genentech, Inc. Anti-CD33 antibodies and immunoconjugates
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
RU2689388C1 (ru) 2013-12-16 2019-05-28 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
HK1222577A1 (zh) 2013-12-16 2017-07-07 Genentech Inc. 擬肽化合物及其抗體藥物偶聯物
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
CN112390883A (zh) 2013-12-17 2021-02-23 基因泰克公司 抗cd3抗体及使用方法
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
ES2778498T3 (es) 2013-12-20 2020-08-10 Hoffmann La Roche Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
CN105873616B (zh) 2014-01-03 2020-06-05 豪夫迈·罗氏有限公司 共价连接的多肽毒素-抗体缀合物
KR102278979B1 (ko) 2014-01-03 2021-07-19 에프. 호프만-라 로슈 아게 공유적으로 연결된 헬리카-항-헬리카 항체 접합체 및 그의 용도
ES2895752T3 (es) 2014-01-03 2022-02-22 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
ES2864160T3 (es) 2014-01-06 2021-10-13 Hoffmann La Roche Módulos lanzadera de la barrera hematoencefálica monovalentes
EP2891664A1 (en) * 2014-01-07 2015-07-08 Technische Universität München Novel methods for the stabilisation of immunoglobulin constant domains
RU2686085C2 (ru) 2014-01-10 2019-04-24 Синтон Байофармасьютикалс Б. В. Конъюгаты антитело-лекарственное средство (adc) с дуокармицином, применяемые для лечения рака эндометрия
CN104861067A (zh) * 2014-01-10 2015-08-26 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
US10548985B2 (en) * 2014-01-10 2020-02-04 Birdie Biopharmaceuticals, Inc. Compounds and compositions for treating EGFR expressing tumors
CN104861064A (zh) * 2014-01-10 2015-08-26 博笛生物科技有限公司 靶向表达egfr的肿瘤的化合物和组合物
EP2948184B1 (en) 2014-01-10 2016-03-23 Synthon Biopharmaceuticals B.V. Duocarmycin adcs showing improved in vivo antitumor activity
CN104861063A (zh) * 2014-01-10 2015-08-26 博笛生物科技有限公司 靶向her2阳性肿瘤的化合物和组合物
JP6786392B2 (ja) 2014-01-15 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＦｃＲｎ結合特性が改変され、プロテインＡ結合特性が保持されているＦｃ領域変異体
US10421796B2 (en) * 2014-01-21 2019-09-24 Gray D Shaw Variants of IgG Fc with limited amine groups
EP3096797A1 (en) 2014-01-24 2016-11-30 F. Hoffmann-La Roche AG Methods of using anti-steap1 antibodies and immunoconjugates
MX388168B (es) 2014-02-08 2025-03-19 Genentech Inc Un anticuerpo anti-amiloide beta (a?) monoclonal humanizado para usarse en el tratamiento de enfermedad de alzheimer.
KR20240094017A (ko) 2014-02-08 2024-06-24 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
HK1231400A1 (zh) 2014-02-11 2017-12-22 Seattle Genetics, Inc. 蛋白质的选择性还原
US9518121B2 (en) 2014-02-12 2016-12-13 Genentech, Inc. Anti-Jagged1 antibodies and methods of use
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
WO2015127405A2 (en) 2014-02-21 2015-08-27 Genentech, Inc. Anti-il-13/il-17 bispecific antibodies and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN104788566A (zh) * 2014-03-11 2015-07-22 南京任诺药业有限公司 用于构建放射性同位素偶联标记的ADC药物的改造抗体IgG1-CH-V280C
CN104672330A (zh) * 2014-03-11 2015-06-03 南京任诺药业有限公司 用于构建放射性同位素偶联标记的ADC药物的改造抗体IgG1-CH-N267C
EP3960767A3 (en) * 2014-03-12 2022-06-01 Novartis AG Specific sites for modifying antibodies to make immunoconjugates
NZ724904A (en) 2014-03-14 2023-04-28 Biomolecular Holdings Llc Hybrid immunoglobulin containing non-peptidyl linkage
MX2016011637A (es) 2014-03-14 2017-04-13 Genentech Inc Metodos y composiciones para secrecion de polipeptidos heterologos.
EP3129067B1 (en) 2014-03-19 2023-01-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
RU2688349C2 (ru) 2014-03-21 2019-05-21 Ф. Хоффманн-Ля Рош Аг In vitro прогнозирование времени полужизни антител in vivo
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
MX385936B (es) 2014-03-28 2025-03-11 Xencor Inc Anticuerpos biespecíficos que se unen a cd38 y cd3.
AU2015241037B2 (en) 2014-03-31 2020-10-15 Genentech, Inc. Anti-OX40 antibodies and methods of use
MX2016012779A (es) 2014-03-31 2017-04-27 Genentech Inc Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
US10285955B2 (en) 2014-04-10 2019-05-14 Af Chemicals, Llc Affinity medicant conjugate
US11135182B2 (en) 2014-04-10 2021-10-05 Af Chemicals, Llc Affinity medicant conjugates
EP3129357B1 (en) 2014-04-10 2023-08-23 AF Chemicals LLC Affinity medicant conjugates
HK1232127A1 (zh) 2014-04-11 2018-01-05 Medimmune, Llc 双特异性her2抗体
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
EP3808778A1 (en) 2014-04-18 2021-04-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
KR102430829B1 (ko) 2014-04-25 2022-08-09 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
US10633448B2 (en) 2014-04-25 2020-04-28 Pierre Fabre Medicament IGF-1R antibody-drug-conjugate and its use for the treatment of cancer
HUE052223T2 (hu) 2014-04-25 2021-04-28 Pf Medicament IGF-1R ellenanyag és alkalmazása rák kezelésében célzóeszközként
BR112016024363A2 (pt) 2014-04-25 2017-10-10 Pf Medicament conjugado de anticorpo-fármaco e seu uso para tratamento de câncer
MX2016014160A (es) 2014-05-01 2017-02-16 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos.
KR102419766B1 (ko) * 2014-05-22 2022-07-13 비온디스 비.브이. 항체에 대한 링커 약물의 부위 특이적 접합 및 그 결과로 얻어지는 adc
BR112016027222A2 (pt) 2014-05-22 2018-01-30 Genentech Inc anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
KR102226248B1 (ko) 2014-06-04 2021-03-12 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
KR102557615B1 (ko) 2014-06-06 2023-07-20 레드우드 바이오사이언스 인코포레이티드 항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
KR20170010785A (ko) 2014-06-11 2017-02-01 제넨테크, 인크. 항-lgr5 항체 및 이의 용도
CN107135646B (zh) 2014-06-13 2022-03-15 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
JP2017517552A (ja) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 抗癌剤耐性の治療及び防止方法
AU2015276821A1 (en) 2014-06-20 2017-01-12 Abgenomics International Inc. Anti-folate receptor aplha (FRA) antibody-drug conjugates and methods of using thereof
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
KR20170026362A (ko) 2014-06-26 2017-03-08 에프. 호프만-라 로슈 아게 항-ｂｒｄｕ 항체 및 사용 방법
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
RU2715038C2 (ru) 2014-07-11 2020-02-21 Дженентек, Инк. Антитела анти-pd-l1 и способы их диагностического применения
CN106488775A (zh) 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
EP3194449A1 (en) 2014-07-24 2017-07-26 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
JP6811706B2 (ja) 2014-07-31 2021-01-13 ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー Ｅｐｈａ４に対するヒトモノクローナル抗体及びそれらの使用
ES3034398T3 (en) 2014-08-28 2025-08-18 Bioatla Inc Conditionally active chimeric antigen receptors for modified t-cells
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
CN112546238A (zh) * 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
TW202417447A (zh) 2014-09-03 2024-05-01 美商免疫原公司 細胞毒性苯并二氮呯衍生物
TW201613930A (en) 2014-09-03 2016-04-16 Immunogen Inc Cytotoxic benzodiazepine derivatives
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
WO2016040724A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
PE20170935A1 (es) 2014-09-12 2017-07-13 Genentech Inc Anticuerpos anti-her2 e inmunoconjugados
JP6622293B2 (ja) 2014-09-12 2019-12-18 ジェネンテック， インコーポレイテッド アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
CR20170095A (es) 2014-09-12 2017-07-19 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados referencias recíprocas con solicitudes relacionadas
AU2015317653A1 (en) 2014-09-17 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
KR20170055521A (ko) 2014-09-17 2017-05-19 제넨테크, 인크. 항-her2 항체를 포함하는 면역콘주게이트
EP3262071B8 (en) 2014-09-23 2022-05-18 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
CN108025083B (zh) 2014-10-09 2021-09-03 建新公司 糖工程化的抗体药物缀合物
NZ731966A (en) * 2014-10-16 2019-11-29 Univ Melbourne Novel imaging composition and uses thereof
CN107074938A (zh) 2014-10-16 2017-08-18 豪夫迈·罗氏有限公司 抗‑α‑突触核蛋白抗体和使用方法
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
KR102210104B1 (ko) 2014-10-17 2021-02-01 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
KR101969121B1 (ko) * 2014-10-28 2019-04-15 에스케이텔레콤 주식회사 시스테인 조작된 항체
GB201419185D0 (en) * 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resin
US10011657B2 (en) 2014-10-31 2018-07-03 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
SG11201703448QA (en) 2014-11-03 2017-05-30 Genentech Inc Assays for detecting t cell immune subsets and methods of use thereof
RU2017119231A (ru) 2014-11-03 2018-12-06 Дженентек, Инк. Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40
PT3215528T (pt) 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
BR112017006591A2 (pt) 2014-11-06 2018-01-16 Hoffmann La Roche polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
CA2960297A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
JP2018500882A (ja) 2014-11-10 2018-01-18 ジェネンテック， インコーポレイテッド 腎症の動物モデルおよびそれを治療するための薬剤
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
LT3224275T (lt) 2014-11-14 2020-05-25 F. Hoffmann-La Roche Ag Antigeną surišančios molekulės, apimančios tnf šeimos ligando trimerą
JP6859259B2 (ja) 2014-11-19 2021-04-14 ジェネンテック， インコーポレイテッド ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
SMT202100055T1 (it) 2014-11-19 2021-03-15 Axon Neuroscience Se Anticorpi tau umanizzati nella malattia di alzheimer
CN107001473B (zh) 2014-11-19 2021-07-09 豪夫迈·罗氏有限公司 抗-运铁蛋白受体抗体及使用方法
ES2926673T3 (es) 2014-11-20 2022-10-27 Hoffmann La Roche Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T y antagonistas de la unión al eje de PD-1
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
HRP20211273T1 (hr) 2014-11-26 2021-11-12 Xencor, Inc. Heterodimerna protutijela koja vežu cd3 i cd20
MX2017006918A (es) 2014-11-26 2018-01-25 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cd38.
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
CN107206102A (zh) 2014-12-03 2017-09-26 豪夫迈·罗氏有限公司 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
JP6752204B2 (ja) 2014-12-03 2020-09-09 ジェネンテック， インコーポレイテッド 四級アミン化合物及びその抗体−薬物コンジュゲート
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
BR112017011478A2 (pt) 2014-12-03 2018-02-27 Genentech, Inc. composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante
SG11201704449VA (en) 2014-12-05 2017-06-29 Genentech Inc ANTI-CD79b ANTIBODIES AND METHODS OF USE
SG11201704550XA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
CA2966365A1 (en) 2014-12-10 2016-06-16 Genentech, Inc. Blood brain barrier receptor antibodies and methods of use
TWI617580B (zh) 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
PE20171185A1 (es) 2015-01-14 2017-08-22 Bristol Myers Squibb Co Dimeros de benzodiazepina unidos con puentes de heteroarileno, conjugados de estos, y sus metodos de preparacion y uso
AR103442A1 (es) 2015-01-16 2017-05-10 Juno Therapeutics Inc Anticuerpos y receptores de antígenos quiméricos específicos de ror1
WO2016117346A1 (en) 2015-01-22 2016-07-28 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
JP6932649B2 (ja) * 2015-02-16 2021-09-08 ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ Ｃｌ及び／又はｃｈ１が突然変異された薬剤コンジュゲーションのための抗体
MA41645A (fr) * 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CA2978256A1 (en) 2015-03-06 2016-09-15 Genentech, Inc. Ultrapurified dsba and dsbc and methods of making and using the same
EP4115910A1 (en) 2015-03-09 2023-01-11 Heidelberg Pharma Research GmbH Amatoxin-antibody conjugates
TWI719967B (zh) 2015-03-09 2021-03-01 美商艾澤西公司 結合至ｆｌｔ３蛋白之抗體藥物結合物（ａｄｃ）
JP2018511797A (ja) 2015-03-16 2018-04-26 ジェネンテック， インコーポレイテッド ＩＬ−１３の検出方法及び定量方法並びにＴｈ２関連疾患の診断及び治療における使用
ES2929614T3 (es) 2015-03-17 2022-11-30 Memorial Sloan Kettering Cancer Center Anticuerpos anti-MUC16 y usos de los mismos
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
HK1249048A1 (zh) 2015-04-03 2018-10-26 Eureka Therapeutics, Inc. 靶向afp肽/mhc复合体的构建体及其用途
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
MA53400A (fr) 2015-04-06 2021-08-04 Acceleron Pharma Inc Hétéromultimères alk7: actriib et leurs utilisations
IL304950A (en) 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
US10206942B2 (en) 2015-04-10 2019-02-19 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
JP2018512892A (ja) 2015-04-17 2018-05-24 エルサリー バイオテックＥｌｓａｌｙｓｂｉｏｔｅｃｈ 抗ｔｙｒｏ３抗体及びその使用
JP6815331B2 (ja) * 2015-04-21 2021-01-20 ジェネンテック， インコーポレイテッド 前立腺がんの分析のための組成物及び方法
CN115932273A (zh) 2015-04-24 2023-04-07 豪夫迈·罗氏有限公司 鉴定包含结合多肽的细菌的方法
KR102462811B1 (ko) 2015-04-27 2022-11-04 에이비온 주식회사 항체에 덴드론이 접합된 면역접합체 및 이의 용도
EP3778640A1 (en) 2015-05-01 2021-02-17 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
EP4450524A3 (en) 2015-05-11 2025-05-14 F. Hoffmann-La Roche AG Compositions and methods of treating lupus nephritis
MX2017014381A (es) 2015-05-12 2018-03-02 Genentech Inc Metodos terapeuticos y diagnosticos para cancer.
SI3303400T1 (sl) 2015-05-28 2021-01-29 Genentech, Inc. Na celicah osnovan test za detektiranje anti-CD3 homodimerov
CN107771182A (zh) 2015-05-29 2018-03-06 豪夫迈·罗氏有限公司 人源化抗埃博拉病毒糖蛋白抗体和使用方法
CN106267225B (zh) 2015-05-29 2020-03-06 上海新理念生物医药科技有限公司 三马来酰亚胺型连接子及其应用
JP7144935B2 (ja) 2015-05-29 2022-09-30 ジェネンテック， インコーポレイテッド 癌のための治療方法及び診断方法
JP2018516933A (ja) 2015-06-02 2018-06-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
CN107921132B (zh) 2015-06-04 2021-05-07 圣拉斐尔医院有限公司 糖尿病和igfbp3/tmem219轴抑制剂
EP3302520B1 (en) 2015-06-04 2020-08-05 Ospedale San Raffaele S.r.l. Igfbp3 and uses thereof
PL3303386T3 (pl) 2015-06-05 2025-03-03 Genentech, Inc. Przeciwciała anty-tau i sposoby zastosowania
EP3303399A1 (en) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies
KR20180025888A (ko) 2015-06-08 2018-03-09 제넨테크, 인크. 항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
EP3307780A1 (en) * 2015-06-15 2018-04-18 Genentech, Inc. Antibodies and immunoconjugates
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN107847568B (zh) 2015-06-16 2022-12-20 豪夫迈·罗氏有限公司 抗cll-1抗体和使用方法
EP3310814B1 (en) 2015-06-16 2023-08-02 F. Hoffmann-La Roche AG Humanized and affinity matured antibodies to fcrh5 and methods of use
KR20180012859A (ko) 2015-06-17 2018-02-06 제넨테크, 인크. 항-her2 항체 및 이용 방법
CN107949575B (zh) 2015-06-19 2022-03-08 卫材R&D管理有限公司 Cys80缀合型免疫球蛋白
EP3744732B1 (en) 2015-06-24 2025-09-10 F. Hoffmann-La Roche AG Humanized anti-tau(ps422) antibodies and methods of use
CN107531788B (zh) 2015-06-24 2022-06-21 豪夫迈·罗氏有限公司 对her2和血脑屏障受体特异性的三特异性抗体及使用方法
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
PL3313845T3 (pl) 2015-06-29 2021-01-11 Immunogen, Inc. Koniugaty przeciwciał modyfikowanych cysteiną
EP3313885A1 (en) 2015-06-29 2018-05-02 H. Hoffnabb-La Roche Ag Type ii anti-cd20 antibody for use in organ transplantation
ES2898065T3 (es) 2015-06-29 2022-03-03 Ventana Med Syst Inc Materiales y procedimientos para realizar ensayos histoquímicos para proepirregulina y anfirregulina humanas
CN108449940B (zh) 2015-07-12 2021-06-08 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3331550B1 (en) 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
NZ739721A (en) 2015-08-07 2019-09-27 Imaginab Inc Antigen binding constructs to target molecules
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017027861A1 (en) 2015-08-13 2017-02-16 Amgen Inc. Charged depth filtration of antigen-binding proteins
CN106467575B (zh) * 2015-08-18 2020-07-31 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物
US10906990B2 (en) 2015-08-19 2021-02-02 Riken Antibody with non-natural amino acid introduced therein
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
CN108026180B (zh) 2015-08-28 2022-06-07 豪夫迈·罗氏有限公司 抗羟腐胺赖氨酸抗体及其用途
EP3353206A1 (en) 2015-09-22 2018-08-01 Spring Bioscience Corporation Anti-ox40 antibodies and diagnostic uses thereof
CN116987187A (zh) 2015-09-23 2023-11-03 豪夫迈·罗氏有限公司 抗-vegf抗体的优化的变体
CA2999917A1 (en) 2015-09-24 2017-03-30 Abvitro Llc Hiv antibody compositions and methods of use
MY186016A (en) 2015-09-25 2021-06-14 Genentech Inc Anti-tigit antibodies and methods of use
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CN114057885A (zh) 2015-10-02 2022-02-18 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
CN114773481B (zh) 2015-10-02 2025-04-29 豪夫迈·罗氏有限公司 对pd1和tim3特异性的双特异性抗体
MA43017A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
RU2746409C1 (ru) 2015-10-02 2021-04-13 Ф. Хоффманн-Ля Рош Аг Антитела к pd1 и способы их применения
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
RU2018116402A (ru) 2015-10-07 2019-11-07 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела, четырехвалентные в отношении костимуляторного tnf-рецептора
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) * 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
US9669106B2 (en) 2015-10-26 2017-06-06 Pierre Fabre Medicament Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer
AU2016344663B2 (en) 2015-10-26 2023-09-07 Pierre Fabre Medicament Composition for the treatment of IGF-1R expressing cancer
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
IL295756A (en) 2015-10-29 2022-10-01 Hoffmann La Roche Anti-variant fc-region antibodies and methods of use
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
US10591481B2 (en) 2015-10-30 2020-03-17 Genentech, Inc. Methods of measuring factor D activity and potency of factor D inhibitors
ES2870141T3 (es) 2015-10-30 2021-10-26 Hoffmann La Roche Anticuerpos anti-HtrA1 y procedimientos de uso de los mismos
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
US20170137535A1 (en) 2015-10-30 2017-05-18 Genentech, Inc. Anti-factor d antibody formulations
WO2017079591A2 (en) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
EP3371217B1 (en) 2015-11-08 2025-06-11 F. Hoffmann-La Roche AG Methods of screening for multispecific antibodies
AU2016354009B2 (en) 2015-11-09 2021-05-20 R.P. Scherer Technologies, Llc Anti-CD22 antibody-maytansine conjugates and methods of use thereof
US10550170B2 (en) 2015-11-23 2020-02-04 Acceleron Pharma Inc. Methods for treating vascular eye disorders with actrii antagonists
TWI744261B (zh) * 2015-11-24 2021-11-01 荷蘭商拜恩迪斯公司 抗５ｔ４抗體和抗體-藥物共軛體
ES2810755T3 (es) 2015-11-30 2021-03-09 Abbvie Inc Conjugados fármaco-anticuerpo anti-lrrc15 humano y métodos para su uso
TWI726942B (zh) 2015-11-30 2021-05-11 美商輝瑞股份有限公司 位點專一性ｈｅｒ２抗體藥物共軛體
CA3006610A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. Anti-hulrrc15 antibody drug conjugates and methods for their use
EP3383913A4 (en) 2015-12-04 2019-10-30 Memorial Sloan-Kettering Cancer Center ANTIBODY AGAINST FC RECEPTOR LIKE 5 AND METHOD OF USE
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
WO2017104783A1 (en) 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
IL259256B2 (en) 2015-12-18 2023-02-01 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
KR20180089433A (ko) 2015-12-21 2018-08-08 브리스톨-마이어스 스큅 컴퍼니 부위-특이적 접합을 위한 변이체 항체
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
ES2880731T3 (es) 2016-01-08 2021-11-25 Altrubio Inc Anticuerpos anti-PSGL-1 tetravalentes y usos de los mismos
US11583593B2 (en) * 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
CN114019170A (zh) 2016-01-20 2022-02-08 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
WO2017132279A1 (en) 2016-01-25 2017-08-03 Genentech, Inc. Methods for assaying t-cell dependent bispecific antibodies
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
US20190031743A1 (en) 2016-01-29 2019-01-31 Achaogen, Inc. Screening methods for identifying antibodies that bind cell surface epitopes
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458100B1 (en) 2016-02-12 2020-07-01 Byondis B.V Selective reduction of cysteine-engineered antibodies
HK1259075A1 (zh) 2016-02-17 2019-11-22 Seattle Genetics, Inc. Bcma抗体和其用以治疗癌症和免疫病症的用途
CN107531680B (zh) * 2016-02-26 2020-09-11 江苏恒瑞医药股份有限公司 一种毒素及其中间体的制备方法
KR102500659B1 (ko) 2016-02-29 2023-02-16 제넨테크, 인크. 암에 대한 치료 및 진단 방법
WO2017151947A1 (en) * 2016-03-02 2017-09-08 George Robert Pettit 4-azapodophylotoxins compounds
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
EP3423457B1 (en) 2016-03-04 2021-02-17 H. Hoffnabb-La Roche Ag Process for the preparation of an antibody-rifamycin conjugate
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
WO2017176007A1 (ko) * 2016-04-06 2017-10-12 (주)알테오젠 변형항체를 포함하는 항체-약물 접합체
EP4144377A1 (en) * 2016-04-06 2023-03-08 Alteogen, Inc. Antibody-drug conjugate comprising modified antibody
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
WO2017180864A1 (en) 2016-04-14 2017-10-19 Genentech, Inc. Anti-rspo3 antibodies and methods of use
SG11201808994YA (en) 2016-04-15 2018-11-29 Bioatla Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
JP2019515670A (ja) 2016-04-15 2019-06-13 ジェネンテック， インコーポレイテッド がんをモニタリングし治療するための方法
KR20190003958A (ko) 2016-04-15 2019-01-10 제넨테크, 인크. 암의 치료 및 모니터링 방법
ES2936226T3 (es) 2016-04-15 2023-03-15 Beckman Coulter Inc Macromoléculas fotoactivas y usos de las mismas
WO2017184942A1 (en) 2016-04-21 2017-10-26 Abbvie Stemcentrx Llc Novel anti-bmpr1b antibodies and methods of use
EP3448885A4 (en) 2016-04-26 2020-01-08 R.P. Scherer Technologies, LLC ANTIBODY CONJUGATES AND METHOD FOR THE PRODUCTION AND USE THEREOF
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
SG11201809620UA (en) 2016-05-02 2018-11-29 Hoffmann La Roche The contorsbody - a single chain target binder
IL321475A (en) 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
EP3455254B1 (en) 2016-05-11 2021-07-07 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
JP7089483B2 (ja) 2016-05-11 2022-06-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 修飾された抗テネイシン抗体及び使用方法
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
ES2930255T3 (es) 2016-05-13 2022-12-09 Bioatla Inc Anticuerpos anti-Ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
MX2018014175A (es) 2016-05-17 2020-02-07 Abbvie Biotherapeutics Inc Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
FI3468586T3 (fi) 2016-06-14 2024-10-29 Xencor Inc Bispesifisiä immuuniaktivaatiota vapauttavia vasta-aineita
EA201990017A1 (ru) 2016-06-17 2019-07-31 Чугаи Сейяку Кабусики Кайся Антитела к миостатину и способы их применения
BR112018075516A2 (pt) 2016-06-17 2019-10-01 Genentech Inc purificação de anticorpos multiespecíficos
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
CN109563160B (zh) 2016-06-24 2023-02-28 豪夫迈·罗氏有限公司 抗聚泛素多特异性抗体
EP3475304B1 (en) 2016-06-28 2022-03-23 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
EP3484518B1 (en) 2016-07-07 2024-08-14 The Board of Trustees of the Leland Stanford Junior University Antibody adjuvant conjugates
EP3482205A1 (en) 2016-07-08 2019-05-15 H. Hoffnabb-La Roche Ag Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
SI3496739T1 (sl) 2016-07-15 2021-06-30 Acceleron Pharma Inc. Sestave, ki zajemajo polipeptide actriia, za uporabo pri zdravljenju pljučne hipertenzije
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
AU2017302282B2 (en) 2016-07-27 2024-07-25 Acceleron Pharma Inc. Methods and compositions for treating myelofibrosis
US20240018268A1 (en) 2016-07-29 2024-01-18 Juno Therapeutics, Inc. Anti-idiotypic antibodies against anti-cd19 antibodies
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
ES3034020T3 (en) 2016-08-15 2025-08-12 Hoffmann La Roche Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
JP7023933B2 (ja) 2016-08-19 2022-02-22 ブリストル－マイヤーズ スクイブ カンパニー セコ－シクロプロパピロロインドール化合物、その抗体－薬物コンジュゲート、ならびに製造および使用方法
BR112019003709A2 (pt) * 2016-08-25 2019-05-28 Centre Nat Rech Scient nanopartículas de silício multifuncionalizadas, usos de nanopartículas de silício multifuncionalizadas, composição e métodos para medir um analito por um método in vitro
UY37376A (es) 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN116731197A (zh) 2016-09-19 2023-09-12 豪夫迈·罗氏有限公司 基于补体因子的亲和层析
RU2752785C2 (ru) 2016-09-23 2021-08-04 Дженентек, Инк. Применение антагонистов il-13 для лечения атопического дерматита
AU2017338827B2 (en) 2016-10-03 2023-08-31 Juno Therapeutics, Inc. HPV-specific binding molecules
CN110198743B (zh) 2016-10-05 2023-07-18 艾科赛扬制药股份有限公司 用于治疗肾脏疾病的组合物和方法
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
JP7579056B2 (ja) 2016-10-06 2024-11-07 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
CN117398475A (zh) * 2016-10-08 2024-01-16 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物及其制备方法
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CA3040504A1 (en) 2016-10-14 2018-04-19 Xencor, Inc. Il15/il15ra heterodimeric fc-fusion proteins
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
EP4124343A1 (en) 2016-10-20 2023-02-01 I-Mab Biopharma US Limited Novel cd47 monoclonal antibodies and uses thereof
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018085769A1 (en) * 2016-11-07 2018-05-11 Seattle Genetics, Inc. Distribution of engineered-cysteine caps
CN110099682B (zh) 2016-11-14 2023-03-31 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
WO2018091724A1 (en) 2016-11-21 2018-05-24 Cureab Gmbh Anti-gp73 antibodies and immunoconjugates
WO2018098258A2 (en) 2016-11-23 2018-05-31 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
BR112019011186A2 (pt) 2016-12-01 2019-10-08 Regeneron Pharmaceuticals, Inc. conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
CA3045294A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
TWI787219B (zh) 2016-12-07 2022-12-21 美商建南德克公司 抗-ｔａｕ抗體及使用方法
JP2020511408A (ja) 2016-12-12 2020-04-16 ジェネンテック， インコーポレイテッド 抗ｐｄ−ｌ１抗体及び抗アンドロゲン薬を使用してがんを治療する方法
KR20190095329A (ko) 2016-12-13 2019-08-14 볼트 바이오테라퓨틱스 인코퍼레이티드 항체-애쥬번트 접합체
KR102669762B1 (ko) 2016-12-19 2024-05-30 에프. 호프만-라 로슈 아게 표적화된 4-1bb(cd137) 작용물질과의 병용 요법
IL267406B2 (en) 2016-12-20 2025-05-01 Hoffmann La Roche Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
CR20190309A (es) 2017-01-03 2019-08-21 Hoffmann La Roche Moleculas de unión de3 antígeno biespecíficas que comprenden el clon 20h4.9 anti-4-1bb
EP3568468A4 (en) 2017-01-12 2020-12-30 Eureka Therapeutics, Inc. RECOMBINATION PRODUCTS TARGETING PEPTIDE HISTONE H3 / MHC COMPLEXES AND THEIR USES
ES2871001T3 (es) 2017-02-08 2021-10-28 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
PL3579883T3 (pl) 2017-02-08 2022-01-24 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
UA126574C2 (uk) 2017-02-10 2022-11-02 Дженентек, Інк. Антитіло проти триптази, його композиція та застосування
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
EP3589754B1 (en) 2017-03-01 2023-06-28 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
TWI839327B (zh) 2017-03-22 2024-04-21 美商建南德克公司 用於治療眼部病症之最佳化之抗體組合物
WO2018183175A1 (en) 2017-03-28 2018-10-04 Genentech, Inc. Methods of treating neurodegenerative diseases
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018178076A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
RU2761377C2 (ru) 2017-04-03 2021-12-07 Ф. Хоффманн-Ля Рош Аг Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
ES2955852T3 (es) 2017-04-03 2023-12-07 Hoffmann La Roche Anticuerpos de unión a STEAP-1
PE20200006A1 (es) 2017-04-04 2020-01-06 Hoffmann La Roche Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
FI3606955T3 (fi) 2017-04-05 2025-01-08 Hoffmann La Roche Pd1:een ja lag3:een spesifisesti sitoutuvia bispesifisiä vasta-aineita
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
DK3609540T5 (da) 2017-04-14 2024-09-02 Bolt Biotherapeutics Inc Fremgangsmåde til immunkonjugatsyntese
EP3610010A4 (en) 2017-04-14 2021-02-24 Kodiak Sciences Inc. COMPLEMENT FACTOR-D-ANTAGONIST-ANTIBODIES AND CONJUGATES THEREOF
MX2019012192A (es) 2017-04-14 2020-01-21 Genentech Inc Métodos de diagnóstico y terapéuticos para el cáncer.
WO2018192944A1 (en) 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
JP7679175B2 (ja) 2017-04-20 2025-05-19 エータイアー ファーマ， インコーポレイテッド 肺の炎症を治療するための組成物および方法
CR20190480A (es) 2017-04-21 2019-11-20 Genentech Inc Uso de antagonistas de klk5 para el tratamiento de una enfermedad
IL270138B2 (en) 2017-04-26 2025-08-01 Eureka Therapeutics Inc Structures that specifically recognize glypican 3 and their uses
KR102769634B1 (ko) 2017-04-27 2025-02-19 테사로, 인코포레이티드 림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
IL270453B2 (en) 2017-05-05 2025-05-01 Fusion Pharmaceuticals Inc Pharmacokinetic enhancements of bifunctional chelates and uses thereof
BR112019023249A8 (pt) 2017-05-05 2021-02-23 Centre For Probe Dev And Commercialization anticorpos monoclonais igf-1r e usos dos mesmos
CN117683836A (zh) 2017-05-09 2024-03-12 辛利斯生物制药有限责任公司 用于修饰微囊藻毒素和节球藻毒素的方法
CN110730787B (zh) * 2017-05-09 2023-11-03 辛利斯生物制药有限责任公司 修饰的微囊藻毒素和节球藻毒素
US11116835B2 (en) 2017-05-10 2021-09-14 Fred Hutchinson Cancer Research Center Epstein Barr virus antibodies, vaccines, and uses of the same
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
JP7366755B2 (ja) 2017-05-30 2023-10-23 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ 抗ダブルコルチン様キナーゼ１抗体および使用方法
US20210246227A1 (en) 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
JP2020523319A (ja) * 2017-06-07 2020-08-06 シルバーバック セラピューティックス インコーポレイテッド 免疫調節化合物の抗体コンジュゲートおよびその使用
ES2988683T3 (es) 2017-06-14 2024-11-21 Adc Therapeutics Sa Pautas posológicas para la administración de un CAF anti-CD19
CN110869394A (zh) * 2017-06-16 2020-03-06 伊莱利利公司 工程改造的抗体化合物及其缀合物
MA49517A (fr) 2017-06-30 2020-05-06 Xencor Inc Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
AU2018304458B2 (en) 2017-07-21 2021-12-09 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
EP3668545A2 (en) 2017-08-16 2020-06-24 Bristol-Myers Squibb Company Prodruggable antibodies, prodrugs thereof, and methods of use and making
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
SG11202000358YA (en) 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
KR20220156974A (ko) 2017-09-20 2022-11-28 주식회사 피에이치파마 타일란스타틴 유사체
SG11202001401TA (en) 2017-09-22 2020-04-29 Immunogen Inc Separation of triple-light chain antibodies using cation exchange chromatography
IL273424B2 (en) 2017-09-22 2024-09-01 Wuxi Biologics Ireland Ltd Novel bispecific cd3/cd19 polypeptide complexes
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
EP3690050A4 (en) 2017-09-29 2021-06-16 Chugai Seiyaku Kabushiki Kaisha MULTISPECIFIC ANTIGENBINDING MOLECULE WITH BLOOD CLOG FACTOR VIII (FVIII) COFACTOR FUNCTION SUBSTITUATING ACTIVITY AND PHARMACEUTICAL FORMULATION WITH THIS MOLECULE AS THE ACTIVE SUBSTANCE
EP3692060A1 (en) 2017-10-03 2020-08-12 Merck Patent GmbH Cysteine engineered antigen-binding molecules
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
US11912754B2 (en) 2017-10-12 2024-02-27 Immunowake Inc. VEGFR-antibody light chain fusion protein
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
PE20210844A1 (es) 2017-11-01 2021-05-10 Hoffmann La Roche Contorsbodies 2 + biespecificos
JP2021501162A (ja) 2017-11-01 2021-01-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 標的ｏｘ４０アゴニストとの併用療法
CN111246884A (zh) 2017-11-01 2020-06-05 豪夫迈·罗氏有限公司 新颖的含有tnf家族配体三聚体的抗原结合分子
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
AU2018361819B2 (en) 2017-11-02 2025-01-09 Oxford Biotherapeutics Ltd Antibodies and methods of use
CN107789631B (zh) * 2017-11-03 2021-03-16 合肥瀚科迈博生物技术有限公司 抗人ErbB2双表位抗体-药物偶联物及其应用
JP7544597B2 (ja) 2017-11-06 2024-09-03 ジェネンテック， インコーポレイテッド がんの診断及び療法
WO2019094637A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
CN111417409B (zh) 2017-11-14 2022-07-08 麦迪穆有限责任公司 吡咯并苯并二氮杂䓬缀合物
IL316155A (en) 2017-11-29 2024-12-01 Heidelberg Pharma Res Compositions and Methods for the Depletion of CD5(PLUS) CELLS
JP2021506260A (ja) 2017-12-15 2021-02-22 ジュノー セラピューティクス インコーポレイテッド 抗ｃｃｔ５結合分子およびその使用方法
KR102722731B1 (ko) 2017-12-19 2024-10-25 젠코어 인코포레이티드 조작된 il-2 fc 융합 단백질
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
MA51302A (fr) 2017-12-21 2021-03-31 Hoffmann La Roche Anticorps se liant à hla-a2/wt1
US20190211098A1 (en) 2017-12-22 2019-07-11 Genentech, Inc. Use of pilra binding agents for treatment of a disease
KR102845020B1 (ko) 2017-12-28 2025-08-12 난징 레전드 바이오테크 씨오., 엘티디. Pd-l1에 대한 항체 및 변이체
JP7369127B2 (ja) 2017-12-28 2023-10-25 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体
EP3732178A1 (en) 2017-12-28 2020-11-04 ImmunoGen, Inc. Benzodiazepine derivatives
WO2019129677A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Anti-vegf antibodies and methods of use
BR112020013679A2 (pt) 2018-01-04 2020-12-01 Iconic Therapeutics, Inc. anticorpos de fator antitecidual, conjugados anticorpo-fármaco e métodos relacionados
CN111886247A (zh) 2018-01-05 2020-11-03 Ac免疫有限公司 错折叠tdp-43结合分子
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
KR102839330B1 (ko) 2018-01-15 2025-07-30 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
MA51676A (fr) 2018-01-26 2021-05-05 Hoffmann La Roche Protéines de fusion il-22 fc et procédés d'utilisation
ES2932861T3 (es) 2018-01-26 2023-01-27 Hoffmann La Roche Composiciones de IL-22 Fc y procedimientos de uso
CA3089287A1 (en) 2018-02-08 2019-08-15 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
JP7418337B2 (ja) 2018-02-09 2024-01-19 ジェネンテック， インコーポレイテッド マスト細胞媒介性炎症性疾患の治療法及び診断法
CA3090538A1 (en) 2018-02-09 2019-08-15 Acceleron Pharma, Inc. Methods for treating heterotopic ossification
JP7350756B2 (ja) 2018-02-14 2023-09-26 アバ セラピューティクス アーゲー 抗ヒトｐｄ－ｌ２抗体
JP2021514354A (ja) 2018-02-21 2021-06-10 ジェネンテック， インコーポレイテッド ＩＬ−２２Ｆｃ融合タンパク質による治療のための投与
AU2019225249A1 (en) 2018-02-26 2020-09-17 Genentech, Inc. Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
EP3533460A1 (en) 2018-03-02 2019-09-04 Diaccurate Therapeutic anti-spla2-gib antibodies and the uses thereof
JP7328261B2 (ja) 2018-03-06 2023-08-16 インケア バイオテック， エルエルシー セリンプロテアーゼ阻害剤カザル（ｓｐｉｋ）組成物および方法
HRP20231280T1 (hr) 2018-03-13 2024-02-02 Zymeworks Bc Inc. Anti-her2 biparatopski antitijelo-konjugati lijeka i načini uporabe
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
WO2019175071A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
EP3765522A4 (en) 2018-03-14 2022-05-18 Beijing Xuanyi Pharmasciences Co., Ltd. ANTI-CLAUDIN 18.2 ANTIBODIES
IL277375B2 (en) 2018-03-15 2025-08-01 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
EP3768720A4 (en) 2018-03-20 2022-01-05 Wuxi Biologics Ireland Limited NEW ANTI-BODY ANTI-LAG-3 POLYPEPTIDE
WO2019179420A1 (en) 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-tim-3 antibodies
AU2019244481A1 (en) 2018-03-28 2020-10-01 Axon Neuroscience Se Antibody-based methods of detecting and treating Alzheimer's disease
WO2019191630A1 (en) 2018-03-29 2019-10-03 Abbvie Inc. Selective reduction of antibodies
KR20200135510A (ko) 2018-03-29 2020-12-02 제넨테크, 인크. 포유류 세포들에서 젖분비자극 활성의 조절
US11958903B2 (en) 2018-03-30 2024-04-16 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
MX2020010460A (es) 2018-04-05 2021-01-29 Juno Therapeutics Inc Receptores de células t, y células diseñadas que expresan los mismos.
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP7418346B2 (ja) 2018-04-13 2024-01-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ４－１ＢＢＬを含むＨｅｒ２標的化抗原結合分子
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
JP2021521784A (ja) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
CN110464842B (zh) 2018-05-11 2022-10-14 信达生物制药(苏州)有限公司 包含抗pcsk9抗体的制剂及其用途
CN119405832A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
JP7398396B2 (ja) 2018-06-01 2023-12-14 ノバルティス アーゲー Ｂｃｍａに対する結合分子及びその使用
US11987629B2 (en) 2018-06-01 2024-05-21 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and uses thereof for treating disease or condition
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
EP3805400A4 (en) 2018-06-04 2022-06-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule showing changed half-life in cytoplasm
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CN111867630B (zh) 2018-06-17 2023-10-13 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
WO2019245991A1 (en) 2018-06-18 2019-12-26 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
WO2019243825A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Small molecule modulators of human sting, conjugates and therapeutic applications
PE20211091A1 (es) 2018-07-02 2021-06-14 Amgen Inc Proteina de union al antigeno anti-steap1
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2020007817A1 (en) 2018-07-04 2020-01-09 F. Hoffmann-La Roche Ag Novel bispecific agonistic 4-1bb antigen binding molecules
MX2021000745A (es) 2018-07-20 2021-03-26 Surface Oncology Inc Composiciones anti-cd112r y metodos.
CN112739339B (zh) 2018-07-23 2024-12-27 海德堡医药研究有限责任公司 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
AU2019311077B2 (en) 2018-07-23 2025-05-29 Heidelberg Pharma Research Gmbh Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
WO2020023871A1 (en) 2018-07-27 2020-01-30 Promega Corporation Quinone-containing conjugates
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
CA3106829A1 (en) 2018-08-03 2020-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing two antigen-binding domains that are linked to each other
SG10202106830VA (en) 2018-08-10 2021-08-30 Chugai Pharmaceutical Co Ltd Anti-cd137 antigen-binding molecule and utilization thereof
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
KR102353086B1 (ko) * 2018-09-07 2022-01-20 아주대학교산학협력단 신규 면역독소 제조방법
CA3110750A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cd33 and constructs thereof
KR20210063330A (ko) 2018-09-19 2021-06-01 제넨테크, 인크. 방광암에 대한 치료 및 진단 방법
EP3861025A1 (en) 2018-10-01 2021-08-11 F. Hoffmann-La Roche AG Bispecific antigen binding molecules with trivalent binding to cd40
US11242396B2 (en) 2018-10-01 2022-02-08 Hoffmann-La Roche Inc. Bispecific antigen binding molecules comprising anti-FAP clone 212
EP3632929A1 (en) 2018-10-02 2020-04-08 Ospedale San Raffaele S.r.l. Antibodies and uses thereof
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
KR20210079311A (ko) 2018-10-18 2021-06-29 제넨테크, 인크. 육종성 신장암에 대한 진단과 치료 방법
AU2019361281A1 (en) 2018-10-19 2021-04-29 Medimmune Limited Pyrrolobenzodiazepine conjugates
EP3866856A1 (en) 2018-10-19 2021-08-25 MedImmune Limited Pyrrolobenzodiazepine conjugates
EP3873534A1 (en) 2018-10-29 2021-09-08 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
EP3873524B8 (en) 2018-10-30 2025-04-09 ImmunoGen, Inc. Methods of treatment using anti-cd123 immunoconjugates
US12168696B2 (en) 2018-11-16 2024-12-17 Memorial Sloan Kettering Cancer Center Antibodies to mucin-16 (MUC16), encoding polynucleotides and methods of treating MUC16-positive cancer
JP7517999B2 (ja) 2018-11-27 2024-07-17 イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド 抗ＩＬ－２３ｐ１９抗体およびその使用
EP3902835A4 (en) 2018-11-27 2022-08-17 Staidson (Beijing) Biopharmaceuticals Co., Ltd. ANTIBODIES SPECIFICALLY RECOGNIZING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR ALPHA AND USES THEREOF
CA3121573A1 (en) 2018-12-03 2020-06-11 Agensys, Inc. Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
JP7671248B2 (ja) 2018-12-05 2025-05-01 ジェネンテック， インコーポレイテッド がんの免疫療法のための診断方法及び診断用組成物
KR20210100668A (ko) 2018-12-06 2021-08-17 제넨테크, 인크. 항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
EP3667323B1 (en) 2018-12-11 2024-11-13 AF Chemical LLC Methods, compositions and devices for treating cancer with illudofulvenes
CN113271981B (zh) 2018-12-13 2025-04-11 卫材R&D管理有限公司 荷伯希二烯抗体-药物缀合物及使用方法
US11584825B2 (en) 2018-12-14 2023-02-21 Beckman Coulter, Inc. Polymer dye modification and applications
TW202035442A (zh) 2018-12-20 2020-10-01 美商建南德克公司 經修飾之抗體Fc及其使用方法
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
SG11202106658XA (en) 2018-12-21 2021-07-29 Regeneron Pharma Rifamycin analogs and antibody-drug conjugates thereof
PH12021551487A1 (en) 2018-12-21 2022-04-11 Hoffmann La Roche Tumor-targeted agonistic cd28 antigen binding molecules
CN113195531B (zh) 2018-12-21 2025-03-04 豪夫迈·罗氏有限公司 与VEGF和IL-1β结合的抗体及其使用方法
AU2019405782A1 (en) 2018-12-21 2021-06-17 23Andme, Inc. Anti-IL-36 antibodies and methods of use thereof
MX2021007307A (es) 2018-12-21 2021-07-07 Hoffmann La Roche Anticuerpos que se unen a cd3.
EP3898683A1 (en) 2018-12-21 2021-10-27 F. Hoffmann-La Roche AG Tumor-targeted superagonistic cd28 antigen binding molecules
JP7650802B2 (ja) 2018-12-30 2025-03-25 エフ． ホフマン－ラ ロシュ アーゲー 抗ウサギｃｄ１９抗体および使用方法
BR112021014276A2 (pt) 2019-01-22 2021-09-28 Genentech, Inc. Anticorpos iga isolados, moléculas de fusão igg-iga isoladas, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, para tratar um indivíduo, para aumentar a expressão de dímeros, trímeros ou tetrâmeros, para aumentar a produção de polímeros, para aumentar a produção de dímeros, para aumentar a produção de um polímero, para diminuir a produção de polímeros, para aumentar a expressão transitória de um anticorpo, para expressar dímeros de moléculas de fusão, para expressar dímeros, trímeros ou tetrâmeros, para purificar um anticorpo, para purificar um estado oligomérico de um anticorpo, composição farmacêutica e uso do anticorpo
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
EP3915581A4 (en) 2019-01-24 2023-03-22 Chugai Seiyaku Kabushiki Kaisha NOVEL CANCER ANTIGENS AND ANTIBODIES OF THESE ANTIGENS
CA3123303A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
EP3693063A1 (en) 2019-02-06 2020-08-12 Diaccurate Methods and compositions for treating cancer
US11478553B2 (en) 2019-02-15 2022-10-25 Wuxi Biologies Ireland Limited Process for preparing antibody-drug conjugates with improved homogeneity
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN114127112A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
WO2020172596A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and thereof
AU2020224154B2 (en) 2019-02-21 2025-05-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US12465640B2 (en) 2019-02-25 2025-11-11 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ECM-affinity peptides linked to anti-inflammatory agents
CN113710706A (zh) 2019-02-27 2021-11-26 豪夫迈·罗氏有限公司 用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
MX2021010390A (es) 2019-03-01 2021-11-17 Xencor Inc Anticuerpos heterodimericos que se unen a enpp3 y cd3.
MX2021010565A (es) 2019-03-08 2021-10-13 Genentech Inc Metodos para detectar y cuantificar proteinas asociadas a la membrana en vesiculas extracelulares.
WO2020181846A1 (zh) * 2019-03-11 2020-09-17 凯惠科技发展(上海)有限公司 一种含半胱氨酸的抗体、药物偶联物及其应用
AU2020236015B9 (en) 2019-03-14 2024-11-28 Genentech, Inc. Treatment of cancer with HER2XCD3 bispecific antibodies in combination with anti-HER2 MAB
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
KR20220022112A (ko) 2019-03-21 2022-02-24 이뮤노젠 아이엔씨 세포-결합 제제-약물 콘쥬게이트를 준비하는 방법
PH12021552363A1 (en) 2019-03-29 2022-09-05 Medimmune Ltd Compounds and conjugates thereof
CA3135032A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
AU2020256828A1 (en) 2019-04-10 2021-11-18 Nankai University Anti-CD40 antibody and use thereof
JP7301155B2 (ja) 2019-04-12 2023-06-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト リポカリンムテインを含む二重特異性抗原結合分子
TW202043291A (zh) 2019-04-19 2020-12-01 美商建南德克公司 抗mertk抗體及使用方法
AU2020263959A1 (en) 2019-04-24 2021-11-25 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
EP3968993A1 (en) 2019-05-14 2022-03-23 F. Hoffmann-La Roche AG Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma
UY38700A (es) 2019-05-20 2020-12-31 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
PH12021552938A1 (en) 2019-05-23 2022-07-25 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
TWI870412B (zh) 2019-06-05 2025-01-21 美商建南德克公司 過載層析管柱之再生方法
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
AU2020291014B2 (en) 2019-06-13 2025-06-05 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
CA3141378A1 (en) 2019-06-26 2020-12-30 F. Hoffmann-La Roche Ag Fusion of an antibody binding cea and 4-1bbl
WO2020260326A1 (en) 2019-06-27 2020-12-30 F. Hoffmann-La Roche Ag Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
JP2022540395A (ja) 2019-06-29 2022-09-15 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 細胞結合性分子－チューブリシン誘導体共役体及びその調製方法
EP3994172A1 (en) 2019-07-03 2022-05-11 Oxford BioTherapeutics Ltd Antibodies and methods of use
CN114174341A (zh) 2019-07-08 2022-03-11 英凯尔生物科技有限责任公司 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体、免疫缀合物和使用方法
WO2021004446A1 (en) 2019-07-09 2021-01-14 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing pseudomonas pcrv and uses thereof
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
CN117838878A (zh) * 2019-07-19 2024-04-09 免疫传感器治疗股份有限公司 抗体-sting激动剂缀合物及其在免疫疗法中的用途
EP4003961A2 (en) 2019-07-25 2022-06-01 Curadev Pharma Pvt. Ltd. Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
CN114174338A (zh) 2019-07-31 2022-03-11 豪夫迈·罗氏有限公司 与gprc5d结合的抗体
BR112022001460A2 (pt) 2019-07-31 2022-03-22 Hoffmann La Roche Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
EP4007773A1 (en) 2019-08-06 2022-06-08 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
US20210040174A1 (en) * 2019-08-08 2021-02-11 Navrogen, Inc. Composition and Use of Humoral Immune Suppressor Antagonists for the Treatment of Humoral Immune Suppressed Diseases
WO2021031930A1 (zh) * 2019-08-19 2021-02-25 沈阳药科大学 抗体的突变体及其应用
EP3786180A1 (en) 2019-08-27 2021-03-03 Diaccurate Antibodies and the uses thereof
EP4025254A1 (en) 2019-09-03 2022-07-13 Bolt Biotherapeutics, Inc. Aminoquinoline compounds, immunoconjugates, and uses thereof
US20240043512A1 (en) 2019-09-11 2024-02-08 Imcare Biotech, Llc Epitopes of anti-serine protease inhibitor kazal (spik) antibodies
KR20220062304A (ko) 2019-09-12 2022-05-16 제넨테크, 인크. 루푸스 신장염을 치료하는 조성물과 방법
AR119997A1 (es) 2019-09-18 2022-01-26 Genentech Inc Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
CA3147179A1 (en) 2019-09-20 2021-03-25 Joseph Haw-Ling Lin Dosing for anti-tryptase antibodies
EP4034160A1 (en) 2019-09-27 2022-08-03 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
MX2022003610A (es) 2019-09-27 2022-04-20 Genentech Inc Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
BR112022006001A2 (pt) 2019-09-30 2022-07-12 Bolt Biotherapeutics Inc Imunoconjugado, composto de 8-amido-2-aminobenzazepina-ligante, composto de 5-amino-pirazoloazepina-ligante, composto de aminoquinolina-ligante, uso de um imunoconjugado e métodos para tratar câncer e para preparar um imunoconjugado
CA3154710A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CR20220166A (es) 2019-10-18 2022-06-15 Genentech Inc Métodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes
KR102235549B1 (ko) * 2019-10-22 2021-04-02 주식회사 바이오맥스 항체-약물 복합체 형성을 위한 이관능성 링커와 시스테인이 태그된 스파이태그/캐쳐를 이용한 고효율 접합 키트
MX2022004875A (es) 2019-10-25 2022-06-17 Bolt Biotherapeutics Inc Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos.
WO2021080608A1 (en) 2019-10-25 2021-04-29 Medimmune, Llc Branched moiety for use in conjugates
KR20220092580A (ko) 2019-11-06 2022-07-01 제넨테크, 인크. 혈액암의 치료를 위한 진단과 치료 방법
TWI895295B (zh) 2019-11-12 2025-09-01 美商方得生醫療公司 偵測編碼新生抗原之融合基因之方法
KR20220100611A (ko) 2019-11-15 2022-07-15 엔테라 에스.알.엘. Tmem219 항체 및 이의 치료 용도
US20220387618A1 (en) 2019-11-15 2022-12-08 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
JP7781746B2 (ja) 2019-11-21 2025-12-08 エンテラ・エッセ・エッレ・エッレ Ｉｇｆｂｐ３抗体及びその治療的使用
US11591295B2 (en) 2019-11-25 2023-02-28 Af Chemicals Llc Affinity illudofulvene conjugates
KR20220110539A (ko) 2019-12-04 2022-08-08 에이씨 이뮨 에스에이 치료 및 진단용 신규 분자
CN118465272B (zh) 2019-12-04 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
US20230028050A1 (en) 2019-12-06 2023-01-26 Juno Therapeutics, Inc. Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
CN115335399A (zh) 2019-12-06 2022-11-11 朱诺治疗学股份有限公司 针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
AR120741A1 (es) 2019-12-13 2022-03-16 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso
CN110922476A (zh) * 2019-12-16 2020-03-27 蓝怡科技集团股份有限公司 一种生物素偶联抗体及其制备方法和应用
EP4077391A1 (en) 2019-12-18 2022-10-26 Teneofour, Inc. Heavy chain antibodies binding to cd38
EP4076666A1 (en) 2019-12-18 2022-10-26 F. Hoffmann-La Roche AG Antibodies binding to hla-a2/mage-a4
CN114828895A (zh) 2019-12-23 2022-07-29 卫材R&D管理有限公司 制备基于艾日布林的抗体-药物缀合物的方法
UA128549C2 (uk) 2019-12-27 2024-08-07 Чугаі Сейяку Кабусікі Кайся Антитіло до ctla-4 та його застосування
CN113045655A (zh) 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
JP2023509708A (ja) 2020-01-03 2023-03-09 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
WO2021140130A1 (en) 2020-01-09 2021-07-15 F. Hoffmann-La Roche Ag New 4-1bbl trimer-containing antigen binding molecules
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CA3166732A1 (en) 2020-01-22 2021-07-29 Medimmune Limited Compounds and conjugates thereof
TW202140076A (zh) 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
MX2022009101A (es) * 2020-01-23 2022-10-07 Adagene Ag Proteinas heterodimericas con mutaciones fc.
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
TWI895351B (zh) 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
EP3868396A1 (en) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitors and uses thereof
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
AR121462A1 (es) * 2020-02-28 2022-06-08 Genzyme Corp Polipéptidos de unión modificados para conjugación optimizada con drogas
KR20220145859A (ko) 2020-02-28 2022-10-31 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도
JP7715722B2 (ja) 2020-02-28 2025-07-30 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト及びその使用
WO2021178896A1 (en) 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
JP7765397B2 (ja) 2020-03-12 2025-11-06 イミューン－オーエヌシー セラピューティクス，インコーポレーテッド 新規抗ｌｉｌｒｂ４抗体および派生産物
PH12022552371A1 (en) 2020-03-13 2023-12-18 Genentech Inc Anti-interleukin-33 antibodies and uses thereof
WO2021188749A1 (en) 2020-03-19 2021-09-23 Genentech, Inc. Isoform-selective anti-tgf-beta antibodies and methods of use
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
KR20220157445A (ko) 2020-03-24 2022-11-29 제넨테크, 인크. Tie2-결합제 및 사용방법
CA3169908A1 (en) 2020-03-26 2021-09-30 Genentech, Inc. Modified mammalian cells having reduced host cell proteins
EP4126940A1 (en) 2020-03-30 2023-02-08 F. Hoffmann-La Roche AG Antibody that binds to vegf and pdgf-b and methods of use
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
EP4127724A1 (en) 2020-04-03 2023-02-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
KR20230028242A (ko) 2020-04-24 2023-02-28 마렝고 테라퓨틱스, 인크. T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
BR112022021441A2 (pt) 2020-04-24 2022-12-13 Genentech Inc Métodos para tratar linfoma folicular e linfoma difuso de grandes células b e kits
EP4143345A1 (en) 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
CA3176626A1 (en) 2020-05-08 2021-11-11 David Dornan Elastase-substrate, peptide linker immunoconjugates, and uses thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
EP4157881A4 (en) 2020-05-27 2024-10-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. ANTIBODIES THAT SPECIFICALLY RECOGNIZE NERVE GROWTH FACTOR AND THEIR USES
CN116323665A (zh) 2020-05-29 2023-06-23 23和我公司 抗cd200r1抗体及其使用方法
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
WO2021247769A1 (en) 2020-06-02 2021-12-09 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
WO2021248005A1 (en) 2020-06-05 2021-12-09 Eisai R&D Management Co., Ltd. Anti-bcma antibody-drug conjugates and methods of use
IL298302A (en) 2020-06-08 2023-01-01 Hoffmann La Roche Anti-hbv antibodies and methods of use
EP4165415A1 (en) 2020-06-12 2023-04-19 Genentech, Inc. Methods and compositions for cancer immunotherapy
BR112022025801A2 (pt) 2020-06-18 2023-10-03 Hoffmann La Roche Métodos para tratar um paciente e para tratar um paciente com escc avançado, kit, anticorpo, uso de um anticorpo e uso de um antagonista de ligação
WO2021255142A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2021255143A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and folr1
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
PE20231080A1 (es) 2020-06-19 2023-07-17 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19
EP4169948A4 (en) 2020-06-22 2024-07-10 Innovent Biologics (Suzhou) Co., Ltd. ANTI-CD73 ANTIBODIES AND USE THEREOF
US20230235040A1 (en) 2020-06-22 2023-07-27 Almirall, S.A. Anti-il-36 antibodies and methods of use thereof
PH12022553167A1 (en) 2020-06-23 2024-03-04 Hoffmann La Roche Agonistic cd28 antigen binding molecules targeting her2
IL299161A (en) 2020-06-24 2023-02-01 Genentech Inc Cell lines resistant to apoptosis
WO2021260064A1 (en) 2020-06-25 2021-12-30 F. Hoffmann-La Roche Ag Anti-cd3/anti-cd28 bispecific antigen binding molecules
IL299508A (en) 2020-07-01 2023-02-01 Ars Pharmaceuticals Inc Anti-asgr1 antibody conjugates and uses thereof
EP4179332A1 (en) 2020-07-13 2023-05-17 Genentech, Inc. Cell-based methods for predicting polypeptide immunogenicity
MX2023000617A (es) 2020-07-17 2023-02-13 Genentech Inc Anticuerpos anti-notch2 y metodos de uso.
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
AU2021315665A1 (en) 2020-07-29 2023-03-16 Dynamicure Biotechnology Llc Anti-CD93 constructs and uses thereof
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
WO2022031749A1 (en) 2020-08-03 2022-02-10 Genentech, Inc. Diagnostic and therapeutic methods for lymphoma
WO2022029660A1 (en) 2020-08-05 2022-02-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
CN115836122A (zh) 2020-08-07 2023-03-21 基因泰克公司 用于预测多肽免疫原性的基于t细胞的方法
CA3186059A1 (en) 2020-08-13 2022-02-17 Romas Kudirka Pyrazoloazepine immunoconjugates, and uses thereof
WO2022034228A1 (en) 2020-08-14 2022-02-17 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
WO2022040482A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
WO2022046920A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AU2021331076A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
KR20230074487A (ko) 2020-08-26 2023-05-30 마렝고 테라퓨틱스, 인크. Trbc1 또는 trbc2를 검출하는 방법
WO2022043517A2 (en) 2020-08-27 2022-03-03 Cureab Gmbh Anti-golph2 antibodies for macrophage and dendritic cell differentiation
TW202227625A (zh) 2020-08-28 2022-07-16 美商建南德克公司 宿主細胞蛋白質之ＣＲＩＳＰＲ／Ｃａｓ９多重剔除
MX2023002496A (es) 2020-09-04 2023-03-09 Hoffmann La Roche Anticuerpo que se une al factor de crecimiento endotelial vascular a (vegf-a) y a la angiopoyetina 2 (ang2) y metodos de uso.
CR20230146A (es) 2020-09-11 2023-06-07 Medimmune Ltd Moléculas de unión a b7-h4 terapéuticas
IL301269A (en) 2020-09-14 2023-05-01 Ichnos Sciences S A Antibodies that bind to IL1RAP and their uses
EP4214244A1 (en) 2020-09-21 2023-07-26 Genentech, Inc. Purification of multispecific antibodies
JP7641667B2 (ja) 2020-09-28 2025-03-07 アンジティア バイオメディスンズ リミテッド 抗スクレロスチン構築体及びその使用
CN115925994B (zh) 2020-09-30 2023-09-22 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
WO2022076462A1 (en) 2020-10-05 2022-04-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20250320283A1 (en) 2020-10-16 2025-10-16 Ac Immune Sa Antibodies Binding to Alpha-Synuclein for Therapy and Diagnosis
WO2022086957A1 (en) 2020-10-20 2022-04-28 Genentech, Inc. Peg-conjugated anti-mertk antibodies and methods of use
IL300024A (en) 2020-10-20 2023-03-01 Hoffmann La Roche Combination therapy of PD-1 axis binding antagonists and LRRK2 inhibitors
CA3192306A1 (en) 2020-10-20 2022-04-28 Burkhard Ludewig Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
MX2023004715A (es) 2020-10-22 2023-05-10 Nihon Mediphysics Co Ltd Metodo para producir un complejo de circonio radioactivo.
IL302396A (en) 2020-11-04 2023-06-01 Genentech Inc Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
IL302217A (en) 2020-11-04 2023-06-01 Genentech Inc Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies and anti-CD79B drug antibody conjugates
CN117916261A (zh) 2020-11-16 2024-04-19 豪夫迈·罗氏有限公司 与靶向fap的cd40激动剂的组合疗法
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
CA3200051A1 (en) 2020-12-11 2022-06-16 Shelley Erin ACKERMAN Anti-cea immunoconjugates, and uses thereof
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
AU2021398552A1 (en) 2020-12-11 2023-06-29 Bolt Biotherapeutics, Inc. Anti-pd-l1 immunoconjugates, and uses thereof
CN116897054A (zh) 2020-12-11 2023-10-17 博尔特生物治疗药物有限公司 抗her2免疫缀合物及其用途
US20240091370A1 (en) 2020-12-11 2024-03-21 Bolt Biotherapeutics, Inc. Anti-her2 immunoconjugates, and uses thereof
IL303656A (en) 2020-12-17 2023-08-01 Hoffmann La Roche Anti-hla-g antibodies and use thereof
WO2022135467A1 (zh) 2020-12-23 2022-06-30 信达生物制药(苏州)有限公司 抗b7-h3抗体及其用途
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
AU2022206061A1 (en) 2021-01-06 2023-07-06 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022162203A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses
WO2022162201A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses
CN117120084A (zh) 2021-01-28 2023-11-24 维肯芬特有限责任公司 用于调节b细胞介导的免疫应答的方法和手段
JP2024509695A (ja) 2021-02-03 2024-03-05 ジェネンテック， インコーポレイテッド 多重特異性結合タンパク質分解プラットフォームおよび使用方法
WO2022175595A1 (en) 2021-02-16 2022-08-25 Glykos Finland Oy Linker-payloads and conjugates thereof
EP4046996A1 (en) 2021-02-19 2022-08-24 Universität Bielefeld Cryptophycin compounds and conjugates thereof
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
EP4301472A1 (en) 2021-03-05 2024-01-10 Dynamicure Biotechnology LLC Anti-vista constructs and uses thereof
US20250326855A1 (en) 2021-03-05 2025-10-23 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
CN117157319A (zh) 2021-03-09 2023-12-01 Xencor股份有限公司 结合cd3和cldn6的异二聚抗体
US20240392004A1 (en) 2021-03-10 2024-11-28 Immunowake Inc. Immunomodulatory molecules and uses thereof
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
WO2022192647A1 (en) 2021-03-12 2022-09-15 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
KR20230156373A (ko) 2021-03-15 2023-11-14 제넨테크, 인크. 루푸스 신염의 치료 조성물 및 치료 방법
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
JP2024511424A (ja) 2021-03-25 2024-03-13 ダイナミキュア バイオテクノロジー エルエルシー 抗ｉｇｆｂｐ７構築物およびその使用
CA3212907A1 (en) 2021-03-26 2022-09-29 Gary Brandt 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
CA3212926A1 (en) 2021-03-26 2022-09-29 Gary Brandt 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
AU2022253902A1 (en) 2021-04-10 2023-11-02 Genmab A/S Folr1 binding agents, conjugates thereof and methods of using the same
GB202105187D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
EP4323399A4 (en) 2021-04-14 2025-04-09 Kodiak Sciences Inc. Methods of treating an eye disorder
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
WO2022225880A1 (en) 2021-04-19 2022-10-27 Genentech, Inc. Modified mammalian cells
TW202308699A (zh) 2021-04-23 2023-03-01 美商普方生物製藥美國公司 Ｃｄ７０結合劑、其結合物及其使用方法
KR20240000575A (ko) 2021-04-26 2024-01-02 수안주 바이오파마슈티컬 컴퍼니 리미티드 이중특이성 항체약물접합체
AU2022273063A1 (en) 2021-05-12 2023-11-23 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
EP4337317A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Agonists of trem2
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
WO2022246259A1 (en) 2021-05-21 2022-11-24 Genentech, Inc. Modified cells for the production of a recombinant product of interest
EP4346882A1 (en) 2021-05-26 2024-04-10 Oxford BioTherapeutics Ltd Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
WO2022255778A1 (ko) * 2021-06-01 2022-12-08 주식회사 에즈큐리스 Ｉｌ-33 단백질 저해용 화합물의 스크리닝 방법 및 상기 화합물을 포함하는 알러지성 질환 치료용 약학조성물
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
EP4155321A1 (en) 2021-06-04 2023-03-29 Chugai Seiyaku Kabushiki Kaisha Anti-ddr2 antibodies and uses thereof
IL308015A (en) 2021-06-09 2023-12-01 Hoffmann La Roche Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
EP4355785A1 (en) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
TWI864408B (zh) 2021-06-25 2024-12-01 日商中外製藥股份有限公司 抗ctla-4抗體的用途
JP7472405B2 (ja) 2021-06-25 2024-04-22 中外製薬株式会社 抗ｃｔｌａ－４抗体
US20240261426A1 (en) 2021-06-28 2024-08-08 Byondis B.V. Conjugates comprising phosphoantigens and their use in therapy
US20250011448A1 (en) 2021-07-08 2025-01-09 Staidson Biopharma Inc. Antibodies specifically recognizing tnfr2 and uses thereof
JP2024530402A (ja) 2021-07-12 2024-08-21 ジェネンテック， インコーポレイテッド 抗体－リパーゼ結合を減少させるための構造
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス， インコーポレイテッド Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート
EP4370156A1 (en) 2021-07-14 2024-05-22 Lycia Therapeutics, Inc. M6pr cell surface receptor binding compounds and conjugates
US20240343817A1 (en) 2021-07-14 2024-10-17 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibody that specifically recognizes cd40 and application thereof
TW202309097A (zh) 2021-07-14 2023-03-01 美商建南德克公司 抗ｃ－ｃ模體趨化因子受體８（ｃｃｒ８）抗體及其使用方法
JP2024526880A (ja) 2021-07-22 2024-07-19 ジェネンテック， インコーポレイテッド 脳標的化組成物及びその使用方法
KR20240036570A (ko) 2021-07-22 2024-03-20 에프. 호프만-라 로슈 아게 이종이량체 Fc 도메인 항체
WO2023011338A1 (zh) 2021-08-02 2023-02-09 信达生物制药(苏州)有限公司 抗CD79b×CD3双特异性抗体及其用途
US20250215103A1 (en) 2021-08-03 2025-07-03 Hoffmann-La Roche Inc. Bispecific antibodies and methods of use
KR20240107093A (ko) 2021-08-05 2024-07-08 고 테라퓨틱스, 인크. 항-글리코-muc4 항체 및 그의 용도
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
WO2023019239A1 (en) 2021-08-13 2023-02-16 Genentech, Inc. Dosing for anti-tryptase antibodies
JP2024534067A (ja) 2021-08-19 2024-09-18 エフ． ホフマン－ラ ロシュ アーゲー 多価抗バリアントｆｃ領域抗体および使用方法
MX2024002295A (es) 2021-08-27 2024-03-07 Genentech Inc Metodos para tratar las patologias de tau.
JP2024534853A (ja) 2021-08-30 2024-09-26 ジェネンテック， インコーポレイテッド 抗ポリビキチン多重特異性抗体
AU2022339819A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
TW202328188A (zh) 2021-09-03 2023-07-16 美商Ｇｏ治療公司 抗醣化-cmet抗體及其用途
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
CN115975030B (zh) * 2021-09-30 2023-09-26 杭州邦顺制药有限公司 抗cd39抗体-药物偶联物及其用途
MX2024004117A (es) 2021-10-08 2024-04-19 Chugai Pharmaceutical Co Ltd Metodo para preparar formulacion de jeringa precargada.
US20250000995A1 (en) 2021-10-29 2025-01-02 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CA3236417A1 (en) 2021-11-05 2023-05-11 American Diagnostics & Therapy, Llc (Adxrx) Monoclonal antibodies against carcinoembryonic antigens, and their uses
EP4430072A1 (en) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
EP4180061A1 (en) 2021-11-10 2023-05-17 Nerviano Medical Sciences S.r.l. Anthracycline derivative linker reagents, antibody-drug conjugates and methods
IL312566A (en) 2021-11-10 2024-07-01 Astrazeneca Ab molecules and antibodies
JP2024544997A (ja) 2021-11-16 2024-12-05 エイシー イミューン ソシエテ アノニム 治療および診断のための新規分子
AU2022389969A1 (en) 2021-11-16 2024-05-02 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
WO2023089314A1 (en) 2021-11-18 2023-05-25 Oxford Biotherapeutics Limited Pharmaceutical combinations
WO2023088966A1 (en) 2021-11-19 2023-05-25 Adc Therapeutics Sa Anti-psma conjugates
WO2023092099A1 (en) 2021-11-19 2023-05-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
US20230285580A1 (en) 2021-11-19 2023-09-14 Adc Therapeutics Sa Anti-il-13ralpha2 conjugates
EP4445911A4 (en) 2021-12-06 2025-10-22 Beijing Solobio Genetechnology Co Ltd BISPECIFIC ANTIBODY THAT BINDS SPECIFICALLY TO KLEBSIELLA PNEUMONIAE O1 AND O2 ANTIGENS AND COMPOSITION
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
JP2025501522A (ja) 2021-12-17 2025-01-22 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
CA3240585A1 (en) 2021-12-17 2023-06-22 Wenfeng Xu Anti-ox40 antibodies, multispecific antibodies and methods of use
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
EP4460330A1 (en) 2022-01-06 2024-11-13 Virtuoso Binco, Inc. Conjugates, compositions and methods of use
TW202340251A (zh) 2022-01-19 2023-10-16 美商建南德克公司 抗ｎｏｔｃｈ２抗體及結合物及其使用方法
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
IL315043A (en) 2022-02-16 2024-10-01 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
EP4230222A1 (en) 2022-02-17 2023-08-23 Oxsonics Limited Combination therapy with an anti-axl antibody-pbd conjugate and nanocups
WO2023159182A1 (en) 2022-02-18 2023-08-24 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
JP2025507736A (ja) 2022-02-28 2025-03-21 アーデーセー セラピューティクス ソシエテ アノニム 投薬レジメン
AU2023229884A1 (en) 2022-03-09 2024-10-10 Astrazeneca Ab BINDING MOLECULES AGAINST FRα
KR20240162086A (ko) 2022-03-11 2024-11-14 아스트라제네카 아베 항-FRα 항체-약물 접합체 치료법에 대한 점수 산정 방법
JP2025514610A (ja) 2022-03-25 2025-05-09 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｍｓｌｎ抗体及び使用方法
WO2023186756A1 (en) 2022-03-28 2023-10-05 F. Hoffmann-La Roche Ag Interferon gamma variants and antigen binding molecules comprising these
JP2025512832A (ja) 2022-03-30 2025-04-22 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド ポリペプチドコンジュゲートの液体医薬組成物およびその使用の方法
CA3251490A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Hydroxypropylmethylcellulose derivatives for stabilizing polypeptides
AU2022450448A1 (en) 2022-04-01 2024-10-10 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CN119156231A (zh) 2022-04-07 2024-12-17 海德堡医药研究有限责任公司 提高鹅膏蕈毒素-抗体缀合物的治疗指数的方法
CN119156401A (zh) 2022-04-08 2024-12-17 Ac免疫有限公司 抗tdp-43结合分子
AU2023253705A1 (en) 2022-04-13 2024-10-17 F. Hoffmann-La Roche Ag Pharmaceutical compositions of therapeutic proteins and methods of use
CA3243581A1 (en) 2022-04-20 2023-10-26 Kantonsspital St. Gallen ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THAT BIND PANSPECIFICALLY TO GREMLIN-1 AND GREMLIN-2 AND RELATED USES
KR20250006932A (ko) 2022-05-03 2025-01-13 제넨테크, 인크. 항-Ly6E 항체, 면역접합체 및 이들의 용도
CN119487065A (zh) 2022-05-09 2025-02-18 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
AR129268A1 (es) 2022-05-11 2024-08-07 Hoffmann La Roche Anticuerpo que se une a vegf-a e il6 y métodos de uso
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20250136717A1 (en) 2022-05-16 2025-05-01 Byondis B.V. Novel masked antibodies
TWI866210B (zh) 2022-05-17 2024-12-11 大陸商蘇州創勝醫藥集團有限公司 雙功能蛋白質及其製劑和用途
US20250339547A1 (en) 2022-05-20 2025-11-06 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
AU2023284422A1 (en) 2022-06-07 2024-12-19 Genentech, Inc. Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
US20250382354A1 (en) 2022-06-08 2025-12-18 Institute For Research In Biomedicine (Irb) Cross-specific antibodies, uses and methods for discovery thereof
MA71241A (fr) 2022-06-27 2025-04-30 Astrazeneca Ab Combinaisons impliquant des inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique pour traiter le cancer
AU2023305619A1 (en) 2022-07-13 2025-01-23 F. Hoffmann-La Roche Ag Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4558524A1 (en) 2022-07-19 2025-05-28 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4558226A1 (en) 2022-07-19 2025-05-28 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
TW202413646A (zh) 2022-07-22 2024-04-01 美商萊爾免疫藥物股份有限公司 免疫細胞療法
CR20250056A (es) 2022-07-22 2025-03-19 Genentech Inc Moléculas de unión al antígeno anti-steap1 y sus usos.
IL318702A (en) 2022-08-19 2025-03-01 Evive Biotechnology Shanghai Ltd Compositions containing G-CSF and their uses
WO2024044550A1 (en) 2022-08-22 2024-02-29 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof
CN120435310A (zh) 2022-08-26 2025-08-05 朱诺治疗学股份有限公司 对δ样配体3（DLL3）具有特异性的抗体和嵌合抗原受体
CN120153254A (zh) 2022-09-01 2025-06-13 基因泰克公司 膀胱癌的治疗和诊断方法
JP2025531788A (ja) 2022-09-07 2025-09-25 ダイナミキュア バイオテクノロジー エルエルシー 抗ｖｉｓｔａコンストラクト及びその使用
CA3261444A1 (en) 2022-09-09 2024-03-14 MyricX Pharma Limited ANTIBODY-DRUG CONJUGATE INCLUDING AN NMT INHIBITOR AND ITS USE
WO2024067344A1 (zh) 2022-09-27 2024-04-04 舒泰神（北京）生物制药股份有限公司 特异性识别light的抗体及其应用
IL319943A (en) 2022-10-07 2025-05-01 Genentech Inc Methods for treating cancer with anti-C motif chemokine receptor 8 (CCR8) antibodies
AU2023365967A1 (en) 2022-10-20 2025-06-05 Beijing Solobio Genetechnology Co., Ltd. Antibody combination specifically binding to trail or fasl, and bispecific antibody
EP4609201A1 (en) 2022-10-25 2025-09-03 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma
AU2023374571A1 (en) 2022-11-01 2025-04-03 Heidelberg Pharma Research Gmbh Anti-gucy2c antibody and uses thereof
IL320029A (en) 2022-11-08 2025-06-01 Genentech Inc Compositions and methods for treating childhood idiopathic nephrotic syndrome
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules
CN120417937A (zh) 2022-11-17 2025-08-01 赛诺菲 Ceacam5抗体-药物缀合物及其使用方法
WO2024108178A1 (en) 2022-11-18 2024-05-23 Genentech, Inc. Signal amplification and multiplexing using mass tags for ia-lc-ms/ms based assays
TW202436348A (zh) 2022-11-25 2024-09-16 日商中外製藥股份有限公司 蛋白質的製造方法
WO2024121632A1 (en) 2022-12-09 2024-06-13 Crispr Therapeutics Ag Use of anti-cd117 antibody drug conjugate (adc)
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
KR20250135788A (ko) 2022-12-14 2025-09-15 페온 테라퓨틱스 리미티드 세포독성 화합물
WO2024137619A1 (en) 2022-12-20 2024-06-27 Bolt Biotherapeutics, Inc. Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
WO2024133374A1 (en) 2022-12-22 2024-06-27 Byondis B.V. Novel linker drugs comprising phosphoantigens, novel conjugates and their use in therapy
EP4640715A1 (en) 2022-12-23 2025-10-29 Chimagen Biosciences, Ltd Multi-specific polypeptide complex targeting gprc5d
EP4640708A1 (en) 2022-12-23 2025-10-29 Chimagen Biosciences, Ltd Novel anti-gprc5d antibody
EP4637833A2 (en) 2022-12-23 2025-10-29 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
CN117164701A (zh) * 2022-12-27 2023-12-05 优洛生物(上海)有限公司 一种经改造的抗体、其制备方法及其用途
PE20252286A1 (es) 2023-01-18 2025-09-18 Genentech Inc Anticuerpos multiespecificos y usos de estos
EP4651901A1 (en) 2023-01-18 2025-11-26 Lycia Therapeutics, Inc. Cycling lysosomal targeting antibody conjugates
WO2024155748A1 (en) 2023-01-18 2024-07-25 Lycia Therapeutics, Inc. M6pr binding compounds and conjugates
CN120835793A (zh) 2023-01-18 2025-10-24 利西亚治疗公司 用于降解自身抗体的溶酶体靶向双功能分子
WO2024155747A2 (en) 2023-01-18 2024-07-25 Lycia Therapeutics, Inc. Asgpr binding compounds and conjugates
CN120569410A (zh) 2023-01-25 2025-08-29 豪夫迈·罗氏有限公司 与csf1r和cd3结合的抗体
EP4410314A1 (en) 2023-02-02 2024-08-07 ADC Therapeutics SA Combination therapy comprising anti-cd22 antibody-drug conjugate and irak1 inhibitor
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
EP4665399A1 (en) 2023-02-16 2025-12-24 Astrazeneca AB Combination therapies for treatment of cancer with therapeutic binding molecules
KR20250154371A (ko) 2023-02-28 2025-10-28 에자이 알앤드디 매니지먼트 가부시키가이샤 항-psma 항체, 컨쥬게이트 및 이용 방법
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
CN120858109A (zh) 2023-03-10 2025-10-28 基因泰克公司 与蛋白酶的融合物及其用途
EP4428158A1 (en) 2023-03-10 2024-09-11 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Lung cancer targeting human antibodies and therapeutic uses thereof
CN120752058A (zh) 2023-03-10 2025-10-03 诺华股份有限公司 panRAS抑制剂抗体-药物缀合物及其使用方法
EP4428159A1 (en) 2023-03-10 2024-09-11 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Melanoma targeting human antibodies and therapeutic uses thereof
CN120835901A (zh) 2023-03-13 2025-10-24 豪夫迈·罗氏有限公司 采用pd1-lag3双特异性抗体和hla-g t细胞双特异性抗体的组合疗法
WO2024189048A1 (en) 2023-03-13 2024-09-19 Heidelberg Pharma Research Gmbh Subcutaneously administered antibody-drug conjugates for use in cancer treatment
CN120936626A (zh) 2023-03-31 2025-11-11 基因泰克公司 抗αvβ8整合素抗体及使用方法
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
TW202506194A (zh) 2023-04-28 2025-02-16 英商梅迪繆思有限公司 用於治療癌症的ｂ７－ｈ４治療性結合分子
WO2024233341A1 (en) 2023-05-05 2024-11-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2024269754A1 (en) 2023-05-08 2025-10-23 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use
AU2024268933A1 (en) 2023-05-10 2025-11-20 Chugai Seiyaku Kabushiki Kaisha Methods and compositions for treating cancer
WO2024238537A1 (en) 2023-05-16 2024-11-21 F. Hoffmann-La Roche Ag Pd-1 -regulated il-2 immunocytokine and uses thereof
WO2024246086A1 (en) 2023-06-01 2024-12-05 F. Hoffmann-La Roche Ag Immunostimulatory antigen binding molecules that specifically bind to bcma
WO2024246083A1 (en) 2023-06-01 2024-12-05 F. Hoffmann-La Roche Ag Bispecific antibodies targeting bcma and cd28
WO2024254455A1 (en) 2023-06-08 2024-12-12 Genentech, Inc. Macrophage signatures for diagnostic and therapeutic methods for lymphoma
WO2024258743A1 (en) 2023-06-13 2024-12-19 Adcentrx Therapeutics, Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists
WO2024263845A1 (en) 2023-06-22 2024-12-26 Genentech, Inc. Treatment of multiple myeloma
TW202502809A (zh) 2023-06-22 2025-01-16 美商建南德克公司 抗體及其用途
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032070A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
WO2025035040A1 (en) 2023-08-09 2025-02-13 Lycia Therapeutics, Inc. Lysosomal targeting bifunctional molecules for degradation of muscle-specific kinase autoantibodies
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025038492A1 (en) 2023-08-11 2025-02-20 Abalytics Oncology, Inc. Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
WO2025045250A1 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Anti-human factor d antibody constructs and uses thereof
WO2025051254A1 (zh) * 2023-09-08 2025-03-13 信达生物制药(苏州)有限公司 半胱氨酸改造的抗体和免疫缀合物
WO2025064521A1 (en) 2023-09-18 2025-03-27 Profoundbio Us Co. Ultrafiltration / diafiltration purification methods
AR133909A1 (es) 2023-09-25 2025-11-12 Hoffmann La Roche ANTICUERPO QUE SE UNE A C3bBb
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
WO2025072791A2 (en) * 2023-09-29 2025-04-03 Aktis Oncology, Inc. Miniproteins, conjugates & uses thereof
EP4537907A1 (en) 2023-10-10 2025-04-16 Enthera S.r.l. Cd248 inhibitors and uses thereof
WO2025083061A1 (en) 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-napi2b conjugates
WO2025083064A1 (en) 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-asct2 conjugates
WO2025083067A1 (en) 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-claudin-6 conjugates
EP4548936A1 (en) 2023-10-30 2025-05-07 BioNTech SE Antibody-drug conjugates having a tailor-made drug-to-antibody ratio
WO2025099120A1 (en) 2023-11-09 2025-05-15 F. Hoffmann-La Roche Ag Multispecific antibodies with conditional activity
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025111402A1 (en) 2023-11-21 2025-05-30 Board Of Regents Of The University Of Nebraska Anti-amyloid beta antibodies and related compositions and methods thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025109097A2 (en) 2023-11-24 2025-05-30 Heidelberg Pharma Research Gmbh Novel nicotinamide phosphoribosyltransferase inhibitors and uses thereof
EP4566631A1 (en) 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof
WO2025120040A1 (en) 2023-12-06 2025-06-12 Adc Therapeutics Sa Anti-psma antibody drug conjugates comprising exatecan
WO2025125386A1 (en) 2023-12-14 2025-06-19 F. Hoffmann-La Roche Ag Antibodies that bind to folr1 and methods of use
WO2025132503A1 (en) 2023-12-20 2025-06-26 F. Hoffmann-La Roche Ag Antibodies binding to ceacam5
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2025133042A2 (en) 2023-12-22 2025-06-26 F. Hoffmann-La Roche Ag Activatable fusion proteins and methods of use
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
EP4596569A1 (en) 2024-02-05 2025-08-06 Syndivia Site specific antibody drug conjugates and their process of preparation
EP4595982A1 (en) 2024-02-05 2025-08-06 Syndivia Monoconjugates and their process of preparation
WO2025184421A1 (en) 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
US20250381289A1 (en) 2024-02-29 2025-12-18 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
EP4610267A1 (en) 2024-02-29 2025-09-03 Ustav Organicke Chemie a Biochemie AV CR, v.v.i. Cyclic dinucleotides and conjugates thereof with antibodies
WO2025181189A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025184537A1 (en) 2024-03-01 2025-09-04 The Board Of Trustees Of The Leland Stanford Junior University Bio-engineered mitochondria for targeted delivery to cells
WO2025188694A1 (en) 2024-03-05 2025-09-12 Bristol-Myers Squibb Company Tricyclic tlr7 agonists and uses thereof
WO2025188693A1 (en) 2024-03-05 2025-09-12 Bristol-Myers Squibb Company Bicyclic tlr7 agonists and uses thereof
GB202403391D0 (en) 2024-03-08 2024-04-24 Myricx Pharma Ltd Novel compounds and their use in therapy
WO2025199352A2 (en) 2024-03-20 2025-09-25 Juno Therapeutics, Inc. Antibodies specific for solute carrier family 34 member 2 (slc34a2)
WO2025196639A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody-drug conjugates, and uses thereof
WO2025199464A1 (en) 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Anti-trop2 antibody-drug conjugates and methods of use
GB202404476D0 (en) 2024-03-28 2024-05-15 King S College London Cancer
WO2025215060A1 (en) 2024-04-11 2025-10-16 F. Hoffmann-La Roche Ag Antibodies that specifically bind modified oligonucleotides
GB202405758D0 (en) 2024-04-24 2024-06-05 King S College London Compounds
WO2025226808A1 (en) 2024-04-24 2025-10-30 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2025235918A1 (en) 2024-05-10 2025-11-13 Immunogen, Inc. Anti-cd123 immunoconjugates for the treatment of blastic plasmacytoid cell neoplasm
WO2025235924A2 (en) 2024-05-10 2025-11-13 Immunogen, Inc. Anti-cd123 immunoconjugates for the treatment of acute myeloid leukemia
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
GB202407700D0 (en) 2024-05-30 2024-07-17 Francis Crick Institute Ltd F-actin binding agents
WO2025250969A1 (en) 2024-05-31 2025-12-04 Vertex Pharmaceuticals Incorporated Anti-cd74 antibodies, conjugates and uses thereof

Family Cites Families (351)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5316757A (en) 1984-10-18 1994-05-31 Board Of Regents, The University Of Texas System Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups
US5342606A (en) 1984-10-18 1994-08-30 Board Of Regents, The University Of Texas System Polyazamacrocyclic compounds for complexation of metal ions
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2023779A1 (en) 1989-08-23 1991-02-24 Margaret D. Moore Compositions and methods for detection and treatment of epstein-barr virus infection and immune disorders
WO1991003489A1 (en) 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
JPH053790A (ja) 1990-04-19 1993-01-14 Fujisawa Pharmaceut Co Ltd デヒドロペプチダーゼ−ｉ
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
AU9016591A (en) 1990-10-25 1992-05-26 Tanox Biosystems, Inc. Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on B cells
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
CA2407304A1 (en) 1991-03-29 1992-10-15 Genentech, Inc. Human pf4a receptors and their use
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
JP3050424B2 (ja) 1991-07-12 2000-06-12 塩野義製薬株式会社 ヒトエンドセリンリセプター
US5264557A (en) 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
US6153408A (en) 1991-11-15 2000-11-28 Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
US6011146A (en) 1991-11-15 2000-01-04 Institut Pasteur Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
US5480990A (en) 1991-12-10 1996-01-02 The Dow Chemical Company Bicyclopolyazamacrocyclocarboxylic acid complexes for use as contrast agents
US5739294A (en) 1991-12-10 1998-04-14 The Dow Chemical Company Bicyclopol yazamacrocyclophosphonic acid complexes for use as contrast agents
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1994002893A1 (fr) 1992-07-17 1994-02-03 Kabushiki Kaisha Komatsu Seisakusho Panneau d'affichage a fonction graphique intelligent et procede de commande de mise en evidence
AU4924893A (en) * 1992-09-16 1994-04-12 Galagen, Inc. Antibody treatment of (helicobacter pylori)
IL107366A (en) 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5869445A (en) 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
DK0616812T3 (da) 1993-03-24 2000-04-25 Berlex Biosciences Kombination af antihormonforbindelser og bindingsmolekyler til behandling af cancer
US5385893A (en) 1993-05-06 1995-01-31 The Dow Chemical Company Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
US5462725A (en) 1993-05-06 1995-10-31 The Dow Chemical Company 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5773223A (en) 1993-09-02 1998-06-30 Chiron Corporation Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof
US5767237A (en) 1993-10-01 1998-06-16 Teikoku Hormone Mfg. Co., Ltd. Peptide derivatives
ES2166368T3 (es) 1993-12-24 2002-04-16 Merck Patent Gmbh Inmunoconjugados.
RU2170257C2 (ru) 1994-03-17 2001-07-10 Мерк Патент Гмбх Анти-эфрр одноцепочечный fv, химерное анти-эфрр антитело и способ его получения, фармацевтическая композиция для лечения опухолей, средство для диагностики локализации или оценки роста опухоли
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
MX9700535A (es) 1994-07-21 1997-04-30 Akzo Nobel Nv Formulaciones de peroxido de cetona ciclico.
WO2001016318A2 (en) 1999-09-01 2001-03-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5750370A (en) 1995-06-06 1998-05-12 Human Genome Sciences, Inc. Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor
US7166470B2 (en) 1994-10-18 2007-01-23 Symyx Technologies, Inc. Formation of combinatorial arrays of materials using solution-based methodologies
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
ATE205483T1 (de) 1995-03-30 2001-09-15 Pfizer Chinazolinderivate
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
SI1516628T1 (sl) 1995-07-27 2013-10-30 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
US20020193567A1 (en) 1995-08-11 2002-12-19 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1997010846A1 (en) * 1995-09-18 1997-03-27 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
US5834456A (en) 1996-02-23 1998-11-10 The Dow Chemical Company Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
JP3646191B2 (ja) 1996-03-19 2005-05-11 大塚製薬株式会社 ヒト遺伝子
ES2274537T5 (es) 1996-03-27 2015-09-14 Genentech, Inc. Anticuerpos ErbB3
ES2174250T5 (es) 1996-04-12 2010-04-21 Warner-Lambert Company Llc Inhibidores irreversibles de tirosina quinasas.
NZ332598A (en) 1996-05-17 2000-04-28 Schering Corp Human BAS-1 protein, and use as an antagonist for modulating physiology or development of a cell
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6261791B1 (en) 1997-03-10 2001-07-17 The Regents Of The University Of California Method for diagnosing cancer using specific PSCA antibodies
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
CA2281877C (en) 1997-03-10 2010-01-05 The Regents Of The University Of California Psca: prostate stem cell antigen
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
US6319688B1 (en) 1997-04-28 2001-11-20 Smithkline Beecham Corporation Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998051824A1 (en) 1997-05-15 1998-11-19 Abbott Laboratories Reagents and methods useful for detecting disease of the urinary tract
WO1998051805A1 (en) 1997-05-15 1998-11-19 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
CN1277632A (zh) * 1997-10-03 2000-12-20 中外制药株式会社 天然人源化抗体
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20020034749A1 (en) 1997-11-18 2002-03-21 Billing-Medel Patricia A. Reagents and methods useful for detecting diseases of the breast
US6110695A (en) 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
US7005504B2 (en) * 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
CA2323071C (en) 1998-03-13 2011-06-21 The Burnham Institute Molecules that home to various selected organs or tissues
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DE19820190A1 (de) 1998-04-28 1999-11-04 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Pankreas-Tumor
US6534482B1 (en) 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US20030064397A1 (en) 1998-05-22 2003-04-03 Incyte Genomics, Inc. Transmembrane protein differentially expressed in prostate and lung tumors
US20020187472A1 (en) 2001-03-09 2002-12-12 Preeti Lal Steap-related protein
WO2000012130A1 (en) 1998-08-27 2000-03-09 Smithkline Beecham Corporation Rp105 agonists and antagonists
JP4689781B2 (ja) 1998-09-03 2011-05-25 独立行政法人科学技術振興機構 アミノ酸輸送蛋白及びその遺伝子
WO2000020579A1 (en) 1998-10-02 2000-04-13 Mcmaster University Spliced form of erbb-2/neu oncogene
WO2001057188A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
US6858710B2 (en) 1998-12-17 2005-02-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6962980B2 (en) 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030091580A1 (en) 2001-06-18 2003-05-15 Mitcham Jennifer L. Compositions and methods for the therapy and diagnosis of ovarian cancer
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
AU776672B2 (en) 1998-12-30 2004-09-16 Beth Israel Deaconess Medical Center Characterization of a calcium channel family
US20030190669A1 (en) 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
IL144371A0 (en) 1999-01-29 2002-05-23 Corixa Corp Her-2/neu fusion proteins
GB9905124D0 (en) 1999-03-05 1999-04-28 Smithkline Beecham Biolog Novel compounds
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US7312303B2 (en) 1999-05-11 2007-12-25 Genentech, Inc. Anti-PRO4980 antibodies
WO2000069909A1 (en) 1999-05-14 2000-11-23 The United States Of America Through The Department Of Veterans Affairs Isolation and characterization of epidermal growth factor related protein
US7049410B2 (en) 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
AU4952600A (en) 1999-06-03 2000-12-28 Takeda Chemical Industries Ltd. Screening method with the use of cd100
KR100850389B1 (ko) 1999-06-25 2008-08-04 제넨테크, 인크. 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법
BR0012196A (pt) 1999-06-25 2002-03-19 Genentech Inc Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
US7589172B2 (en) 1999-07-20 2009-09-15 Genentech, Inc. PRO256 polypeptides
US7297770B2 (en) 1999-08-10 2007-11-20 Genentech, Inc. PRO6496 polypeptides
US7294696B2 (en) 1999-08-17 2007-11-13 Genentech Inc. PRO7168 polypeptides
US20030206918A1 (en) 1999-09-10 2003-11-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030232056A1 (en) 1999-09-10 2003-12-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030129192A1 (en) 1999-09-10 2003-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2001040309A2 (en) 1999-10-29 2001-06-07 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
US6372907B1 (en) 1999-11-03 2002-04-16 Apptera Corporation Water-soluble rhodamine dye peptide conjugates
EP1235847B1 (en) 1999-11-29 2016-01-20 The Trustees of Columbia University in the City of New York ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA
CA2392510A1 (en) 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
WO2001041787A1 (en) 1999-12-10 2001-06-14 Epimmune Inc. INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
NZ502058A (en) 1999-12-23 2003-11-28 Ovita Ltd Isolated mutated nucleic acid molecule for regulation of ovulation rate
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
DE60043957D1 (de) 1999-12-23 2010-04-15 Zymogenetics Inc Verfahren zur Behandlung von Entzündungen
JP4741139B2 (ja) 1999-12-23 2011-08-03 ザイモジェネティクス， インコーポレイテッド 可溶性インターロイキン−２０レセプター
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US7297333B2 (en) 2000-01-20 2007-11-20 Genentech, Inc. Anti-PRO10268 antibodies
US20020039573A1 (en) 2000-01-21 2002-04-04 Cheever Martin A. Compounds and methods for prevention and treatment of HER-2/neu associated malignancies
US20030224379A1 (en) 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
US20030186372A1 (en) 2000-02-11 2003-10-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001238596A1 (en) 2000-02-22 2001-09-03 Millennium Pharmaceuticals, Inc. 18607, a novel human calcium channel
US20040005561A1 (en) 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2001245280A1 (en) 2000-03-07 2001-09-17 Hyseq, Inc. Novel nucleic acids and polypeptides
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
JP2004521602A (ja) 2000-03-24 2004-07-22 ファハリ サッチオグリュ 前立腺特異的または精巣特異的な新規の核酸分子、ポリペプチド、ならびに診断法および治療法
AU2001250412A1 (en) 2000-03-31 2001-10-08 Ipf Pharmaceuticals Gmbh Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction
US7279294B2 (en) 2000-04-03 2007-10-09 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih Tumor markers in ovarian cancer
AU2001249885A1 (en) 2000-04-07 2001-10-23 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated known g protein-coupled receptors
WO2001088133A2 (en) 2000-05-18 2001-11-22 Lexicon Genetics Incorporated Human semaphorin homologs and polynucleotides encoding the same
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001275437A1 (en) 2000-06-09 2001-12-17 Idec Pharmaceuticals Corporation Gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
AU2001268471A1 (en) 2000-06-16 2002-01-02 Incyte Genomics, Inc. G-protein coupled receptors
EP1383892A2 (en) 2000-06-30 2004-01-28 Incyte Genomics, Inc. Human extracellular matrix and cell adhesion polypeptides
JP2004502417A (ja) 2000-06-30 2004-01-29 アムジェン　インコーポレーテッド Ｂ７様分子およびその使用
CA2406649A1 (en) 2000-06-30 2002-01-10 Human Genome Sciences, Inc. B7-like polynucleotides, polypeptides, and antibodies
WO2002006339A2 (en) 2000-07-03 2002-01-24 Curagen Corporation Proteins and nucleic acids encoding same
US20040044179A1 (en) 2000-07-25 2004-03-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002010187A1 (en) 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
AU2001287639A1 (en) 2000-07-28 2002-02-13 Ulrich Wissenbach Trp8, trp9 and trp10, markers for cancer
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
AU2001283360A1 (en) 2000-08-14 2002-02-25 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
HUP0600780A2 (en) 2000-08-14 2007-01-29 Corixa Corp Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
JP2004520806A (ja) 2000-08-24 2004-07-15 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
WO2002022660A2 (en) 2000-09-11 2002-03-21 Hyseq, Inc. Novel nucleic acids and polypeptides
AR030612A1 (es) 2000-09-12 2003-08-27 Smithkline Beecham Corp Procedimiento e intermedios
US6613567B1 (en) 2000-09-15 2003-09-02 Isis Pharmaceuticals, Inc. Antisense inhibition of Her-2 expression
US7491797B2 (en) 2000-09-15 2009-02-17 Genentech, Inc. PRO6308 polypeptide
DE60121808T2 (de) 2000-09-15 2007-03-29 Zymogenetics, Inc., Seattle Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
AU2001292724B2 (en) 2000-09-18 2005-05-26 Biogen Idec Ma Inc. CRIPTO mutant and uses thereof
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
AU2002215345A1 (en) 2000-10-13 2002-04-22 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
AU2002230659A1 (en) 2000-11-07 2002-05-21 Zymogenetics Inc. Human tumor necrosis factor receptor
US20020150573A1 (en) 2000-11-10 2002-10-17 The Rockefeller University Anti-Igalpha-Igbeta antibody for lymphoma therapy
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
EP1357828A2 (en) 2001-01-12 2003-11-05 University of Medicine and Dentistry of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
US20030119126A1 (en) 2001-01-16 2003-06-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030119119A1 (en) 2001-01-16 2003-06-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2005503760A (ja) 2001-01-24 2005-02-10 プロテイン デザイン ラブス， インコーポレイテッド 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
WO2002060317A2 (en) 2001-01-30 2002-08-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002064775A1 (en) 2001-02-12 2002-08-22 Bionomics Limited Identification of genes involved in the tumourigenic process
AU2002258518A1 (en) 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
JP5232350B2 (ja) 2001-04-17 2013-07-10 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー Ｃａ１２５遺伝子のリピート配列並びに診断および治療的介入のためのその使用
JP2005527180A (ja) 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
AU2002334799B2 (en) 2001-04-26 2009-05-07 Biogen Ma Inc. Cripto-specific antibodies
MXPA03009797A (es) 2001-04-26 2004-01-29 Biogen Inc ANTICUERPOS PARA BLOQUEO DE PROTEiNA CRIPTO Y USO DE LOS MISMOS.
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
WO2002092836A2 (en) 2001-05-11 2002-11-21 Sloan-Kettering Institute For Cancer Research Nucleic acid sequence encoding ovarian antigen, ca125, and uses thereof
ATE446771T1 (de) 2001-05-24 2009-11-15 Zymogenetics Inc Taci-immunoglobulin-fusionsproteine
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
JP2005518185A (ja) 2001-06-04 2005-06-23 キュラジェン コーポレイション 新規タンパク質およびそれをコード化する核酸
AU2002314901A1 (en) 2001-06-04 2002-12-16 Eos Biotechnology, Inc. Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
AU2002320264B2 (en) 2001-06-05 2008-05-01 Exelixis, Inc. GFATs as modifiers of the p53 pathway and methods of use
JP2005505257A (ja) 2001-06-05 2005-02-24 エクセリクシス・インコーポレイテッド ｐ５３経路のモディファイヤーとしてのＩＧｓおよび使用方法
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
WO2002101075A2 (en) 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
JP2005508144A (ja) 2001-06-18 2005-03-31 イオス バイオテクノロジー，インコーポレイティド 卵巣癌の診断方法、卵巣癌のモジュレーターをスクリーニングする組成物及び方法
WO2003004989A2 (en) 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003002717A2 (en) 2001-06-28 2003-01-09 Schering Corporation Biological activity of ak155
US20030120040A1 (en) 2001-06-29 2003-06-26 Genentech, Inc. Secreted and Transmembrane polypeptides and nucleic acids encoding the same
AU2002314433A1 (en) 2001-07-02 2003-01-21 Licentia Ltd. Ephrin-tie receptor materials and methods
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
WO2003003984A2 (en) 2001-07-05 2003-01-16 Curagen Corporation Novel proteins and nucleic acids encoding same
US7446185B2 (en) 2001-07-18 2008-11-04 The Regents Of The University Of California Her2/neu target antigen and use of same to stimulate an immune response
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2003014294A2 (en) 2001-08-03 2003-02-20 Genentech, Inc. Tacis and br3 polypeptides and uses thereof
EP1478772A2 (en) 2001-08-14 2004-11-24 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
US20030092013A1 (en) 2001-08-16 2003-05-15 Vitivity, Inc. Diagnosis and treatment of vascular disease
WO2003018621A2 (en) 2001-08-23 2003-03-06 Oxford Biomedica (Uk) Limited Genes
WO2003029262A2 (en) 2001-08-29 2003-04-10 Vanderbilt University The human mob-5 (il-24) receptors and uses thereof
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
CA2459318C (en) 2001-09-06 2017-09-26 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
CA2459219A1 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
JP2005536439A (ja) 2001-09-18 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断及び治療のための組成物と方法
WO2003025228A1 (en) 2001-09-18 2003-03-27 Proteologics, Inc. Methods and compositions for treating hcap associated diseases
CA2460621A1 (en) 2001-09-19 2003-03-27 Nuvelo, Inc. Novel nucleic acids and polypeptides
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
AU2002327792A1 (en) 2001-09-28 2003-04-07 Bing Yang Diagnosis and treatment of diseases caused by mutations in cd72
AU2002362436A1 (en) 2001-10-03 2003-04-14 Rigel Pharmaceuticals, Inc. Modulators of lymphocyte activation and migration
AU2002362454A1 (en) 2001-10-03 2003-04-14 Origene Technologies, Inc. Regulated breast cancer genes
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2842429A1 (en) 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
EP1525213B1 (en) 2001-10-24 2012-06-27 National Jewish Health Three-dimensional structures of tall-1 and its cognate receptors and modified proteins and methods related thereto
MXPA04003697A (es) 2001-10-31 2005-04-08 Alcon Inc Proteinas morfogenicas de hueso (bmp), receptores de bmp y proteinas de enlace de bmp y su uso en el diagnostico y tratamiento de glaucoma.
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
AU2002363939A1 (en) 2001-11-20 2003-06-10 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
AU2002339691A1 (en) 2001-11-29 2003-06-10 Genset Agonists and antagonists of prolixin for the treatment of metabolic disorders
AU2002349784A1 (en) 2001-12-03 2003-06-17 Asahi Kasei Pharma Corporation Nf-kappab activating genes
WO2003054152A2 (en) 2001-12-10 2003-07-03 Nuvelo, Inc. Novel nucleic acids and polypeptides
WO2003049704A2 (en) * 2001-12-11 2003-06-19 University Of Massachusetts Antibodies to treat cancer
EP1485126A4 (en) * 2001-12-21 2007-03-21 Idexx Lab Inc DOG IMMUNOGLOBULIN VARIABLE DOMAINS, DOG ANTIBODIES, AND METHOD FOR THEIR PRODUCTION AND USE
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20030134790A1 (en) 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
US7452675B2 (en) 2002-01-25 2008-11-18 The Queen's Medical Center Methods of screening for TRPM4b modulators
EP1485130A4 (en) 2002-02-21 2006-11-22 Univ Duke REAGENTS AND THERAPEUTIC METHODS OF AUTOIMMUNE DISEASES
JP2005535290A (ja) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
AU2003224638A1 (en) 2002-03-01 2003-09-16 Exelixis, Inc. PDPK1s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
US20050220798A1 (en) 2002-06-04 2005-10-06 Reinhard Ebner Cancer-linked gene as target for chemotherapy
WO2003097803A2 (en) 2002-05-15 2003-11-27 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
CA2486490A1 (en) 2002-03-19 2003-12-31 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003081210A2 (en) 2002-03-21 2003-10-02 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
WO2003089624A2 (en) 2002-03-25 2003-10-30 Uab Research Foundation Fc receptor homolog, reagents, and uses thereof
AU2003222103A1 (en) 2002-03-28 2003-10-13 Idec Pharmaceuticals Corporation Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
US20030194704A1 (en) 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
JP2005534287A (ja) 2002-04-05 2005-11-17 アジェンシス， インコーポレイテッド 癌の処置および検出において有用な９８ｐ４ｂ６との名称の核酸および対応するタンパク質
WO2003087768A2 (en) 2002-04-12 2003-10-23 Mitokor Targets for therapeutic intervention identified in the mitochondrial proteome
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030224467A1 (en) 2002-04-17 2003-12-04 Osborne C. Kent AIB1 as a prognostic marker and predictor of resistance to endocrine therapy
WO2003093444A2 (en) 2002-05-03 2003-11-13 Incyte Corporation Transporters and ion channels
AU2003232453A1 (en) 2002-05-30 2003-12-19 David K. Bol Human solute carrier family 7 member 11 (hslc7a11)
WO2003101283A2 (en) 2002-06-04 2003-12-11 Incyte Corporation Diagnostics markers for lung cancer
WO2003104270A2 (en) 2002-06-06 2003-12-18 Ingenium Pharmaceuticals Ag Dudulin 2 genes, expression products, non-human animal model: uses in human hematological disease
CN100532549C (zh) 2002-06-06 2009-08-26 肿瘤疗法科学股份有限公司 与人结肠癌相关的基因和多肽
EP1576111A4 (en) 2002-06-07 2006-10-18 Avalon Pharmaceuticals CANCER-ASSOCIATED GENE AS A TARGET FOR CHEMOTHERAPY
AU2003245441A1 (en) 2002-06-12 2003-12-31 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
AU2003247576A1 (en) 2002-06-18 2003-12-31 Archemix Corp. Aptamer-toxin molecules and methods for using same
US20040249130A1 (en) 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
EP1516433B1 (en) 2002-06-20 2012-04-04 Snaptrack Incorporated Reducing cross-interference in a combined gps receiver and communication system
EP1539218A4 (en) 2002-06-20 2007-08-22 Univ California COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
EP2365004B1 (en) 2002-06-21 2016-01-06 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
GB0216081D0 (en) * 2002-07-11 2002-08-21 Imp College Innovations Ltd Methods of making biological materials and uses thereof
AU2003281515A1 (en) 2002-07-19 2004-02-09 Cellzome Ag Protein complexes of cellular networks underlying the development of cancer and other diseases
BR0313033A (pt) 2002-07-25 2007-07-10 Genentech Inc anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica
WO2004032828A2 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
AU2003251471A1 (en) 2002-08-06 2004-02-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5)
ES2361739T3 (es) 2002-08-16 2011-06-21 Immunogen, Inc. Reticulantes con elevada reactividad y solubilidad y su uso en la preparación de conjugados para el suministro dirigido de fármacos de molécula pequeña.
KR20050048615A (ko) 2002-08-19 2005-05-24 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
WO2004020583A2 (en) 2002-08-27 2004-03-11 Bristol-Myers Squibb Company Polynucleotide predictor set for identifying protein tyrosine kinase modulators
WO2004020595A2 (en) 2002-08-29 2004-03-11 Five Prime Therapeutics, Inc. Novel human polypeptides encoded by polynucleotides
AU2002951346A0 (en) 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
CA2496888A1 (en) 2002-09-06 2004-03-18 Mannkind Corporation Epitope sequences
WO2004040000A2 (en) 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof
JP2004113151A (ja) 2002-09-27 2004-04-15 Sankyo Co Ltd 癌遺伝子及びその用途
CA2500978A1 (en) 2002-10-03 2004-04-15 Mcgill University Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
AU2003288918A1 (en) 2002-10-04 2004-05-04 Van Andel Research Institute Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
US7608429B2 (en) 2002-10-31 2009-10-27 Genentech, Inc. Methods and compositions for increasing antibody production
EP2364716A3 (en) 2002-11-08 2012-01-11 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
CA2503621A1 (en) 2002-11-13 2004-05-27 Genentech, Inc. Methods and compositions for diagnosing dysplasia
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
CA2505919A1 (en) 2002-11-15 2004-06-03 The Board Of Trustees Of The University Of Arkansas Ca125 gene and its use for diagnostic and therapeutic interventions
DK1569685T3 (da) 2002-11-15 2012-11-12 Univ Colorado Regents Komplementmodulatorer rettet mod komplementreceptor-2
US20080213166A1 (en) 2002-11-20 2008-09-04 Biogen Idec Inc. Novel Gene Targets and Ligands that Bind Thereto for Treatment and Diagnosis of Colon Carcinomas
EP2410332A1 (en) 2002-11-21 2012-01-25 The University Of Utah Method for identifying purinergic modulators of the olfactory system
WO2004048938A2 (en) 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
AU2003298794A1 (en) * 2002-12-02 2004-06-23 Us Gov Health & Human Serv Recombinant immunotoxin and use in treating tumors
US20070154886A1 (en) 2002-12-06 2007-07-05 Macina Roberto A Composition, splice variants and methods relating to ovarian specific genes and proteins
JP2004198419A (ja) 2002-12-13 2004-07-15 Bayer Healthcare Llc Ｔｉｍｐ１を用いた検出方法
JP4898120B2 (ja) 2002-12-20 2012-03-14 アボット バイオセラピューティクス コーポレイション Ｇｐｒ６４に対する抗体とその利用法
US20050249671A9 (en) 2002-12-23 2005-11-10 David Parmelee Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
EP1597558A2 (en) 2003-01-08 2005-11-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US20050227301A1 (en) 2003-01-10 2005-10-13 Polgen Cell cycle progression proteins
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
US20040171823A1 (en) 2003-01-14 2004-09-02 Nadler Steven G. Polynucleotides and polypeptides associated with the NF-kappaB pathway
WO2004065576A2 (en) 2003-01-15 2004-08-05 Millennium Pharmaceuticals, Inc. Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
AU2004205684A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1594893A2 (en) 2003-02-14 2005-11-16 Sagres Discovery, Inc. Therapeutic targets in cancer
US20030224411A1 (en) 2003-03-13 2003-12-04 Stanton Lawrence W. Genes that are up- or down-regulated during differentiation of human embryonic stem cells
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11938194B2 (en) 2017-02-28 2024-03-26 Seagen Inc. Cysteine mutated antibodies for conjugation

Also Published As

Publication number Publication date
SI1791565T1 (sl) 2016-08-31
IL181584A (en) 2013-08-29
CA2580141A1 (en) 2006-03-30
NZ553500A (en) 2009-11-27
RU2412947C2 (ru) 2011-02-27
KR20070054682A (ko) 2007-05-29
RU2007115040A (ru) 2008-10-27
IL181584A0 (en) 2007-07-04
AU2005286607B2 (en) 2011-01-27
ES2579805T3 (es) 2016-08-16
US20180000962A1 (en) 2018-01-04
JP2008516896A (ja) 2008-05-22
US20110137017A1 (en) 2011-06-09
CN101065151B (zh) 2014-12-10
DK1791565T3 (en) 2016-08-01
AU2005286607A1 (en) 2006-03-30
TR201808537T4 (tr) 2018-07-23
HK1100423A1 (zh) 2007-09-21
NZ580115A (en) 2010-10-29
EP3088004B1 (en) 2018-03-28
EP1791565A2 (en) 2007-06-06
JP2011162565A (ja) 2011-08-25
CN101065151A (zh) 2007-10-31
CN104447992A (zh) 2015-03-25
US7855275B2 (en) 2010-12-21
HUE030079T2 (en) 2017-04-28
BRPI0516284A (pt) 2008-09-02
US20150017188A1 (en) 2015-01-15
EP3088004A1 (en) 2016-11-02
US8309300B2 (en) 2012-11-13
US7521541B2 (en) 2009-04-21
US20100003766A1 (en) 2010-01-07
ES2669510T3 (es) 2018-05-28
EP1791565B1 (en) 2016-04-20
US20090175865A1 (en) 2009-07-09
WO2006034488A3 (en) 2006-09-28
KR101270829B1 (ko) 2013-06-07
US20070092940A1 (en) 2007-04-26
JP4948413B2 (ja) 2012-06-06
WO2006034488A2 (en) 2006-03-30
PL1791565T3 (pl) 2016-10-31

Similar Documents

Publication Publication Date Title
CA2580141C (en) Cysteine engineered antibodies and conjugates
US20230130874A1 (en) Cysteine Engineered Antibodies and Conjugates
CA3220104A1 (en) Cysteine engineered antibodies and conjugates
HK1229700A (en) Cysteine engineered antibodies and conjugates
HK1229700A1 (en) Cysteine engineered antibodies and conjugates
HK1229700B (en) Cysteine engineered antibodies and conjugates
HK1100423B (en) Cysteine engineered antibodies and conjugates
MX2007003404A (es) Anticuerpos y conjugados diseñados de cisteina

Legal Events

Date Code Title Description
EEER Examination request